COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by explaining failures and finding signals of efficacy.

Daniele Focosi[1,#]

Massimo Franchini[2]

Liise-anne Pirofski[3]

Thierry Burnouf[4]

Nigel Paneth[5]

Michael J. Joyner[6]

Arturo Casadevall[7]

[1]North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

[2]Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy; massimo.franchini@asst-mantova.it

[3]Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10467, USA; l.pirofski@einsteinmed.org

[4]Graduate Institute of Biomedical Materials and Tissue Engineering & International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan; thburnouf@gmail.com

[5]Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University, East Lansing, MI 48824, paneth@msu.edu

[6]Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA; joyner.michael@mayo.edu

[7]Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, MD, USA; acasade1@jhu.edu

[#]corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: daniele.focosi@gmail.com

Word count: abstract 250; body 5835.

Keywords: COVID-19; convalescent plasma; randomized clinical trial; propensity score-matched; neutralizing antibodies; viral neutralization tests.

Abbreviations: BSC : best supportive care; CP : convalescent plasma; CCP : COVID-19 convalescent plasma; nAbs : neutralizing antibodies; VNT: viral neutralization test;

Author contributions: D.F. designed the paper, analyzed the data, and wrote the first draft. M.F., M.J.J., T.B., L.P., N.P. and A.C. revised the manuscript. All authors approved the final version.

Abstract

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light into mechanisms of action, safety and efficacy of convalescent plasma using modern evidence-based medicine approaches. Studies ranging from observational case series to randomized controlled trials (RCT) have reported highly variable efficacy results for COVID-19 CP (CCP), resulting in more doubt than certainty. Reasons for CCP success and failure may be hidden in study details, which are usually difficult to explain to physicians and the public but provide fertile ground for designing next-generation studies. In this paper we analyzed variables associated with efficacy such as clinical settings, disease severity, CCP SARS-CoV-2 antibody levels and function, dose, timing of administration (variously defined as time from onset of symptoms, molecular diagnosis, diagnosis of pneumonia, or hospitalization, or by serostatus), outcomes (defined as hospitalization, requirement for ventilation, clinical improvement or mortality), CCP provenance and time for collection, and criteria for efficacy. Focusing only on the results from the 23 available RCT we noted that these were more likely to show signals of efficacy, including reductions in mortality, if the plasma neutralizing titer was ≥ 160 and the time to randomization was ≤ 9 days, consistent with passive antibody therapy efficacy requiring dosing with sufficient antibody. The fact that most studies revealed signals of efficacy despite variability in CCP and its use suggest robust therapeutic effects that become apparent despite the data noise.

Introduction

In the first 21 years of the 21st century humanity has experienced six major epidemics. The agents involved were SARS-CoV, MERS, influenza A(H_1N_1), Ebola, Zika and SARS-CoV-2 viruses. For five of these outbreaks the response included the use of convalescent plasma (CP) (reviewed in (1, 2)) and it was considered for the sixth (Zika virus). The attraction of CP is that it is readily available as soon as there are convalescing survivors, that unlike drugs or monoclonal antibodies it needs no development, and it is polyclonal, cheap and deployable even in resource poor countries. CP has been proposed as a first line response to new pandemics (3) and was deployed during the COVID-19 pandemic in March 2020 in countries that experienced the early waves of disease such as China (4, 5) and Italy (6).

While in early 2020 most clinical use was reported in case series or small phase II clinical trials (7), beginning in late March 2020 the US expanded access program (EAP) generated a large and robust treatment dataset, with insights on safety and optimal use. This database provided the first clear evidence that CP is safe, which was important given that early in the pandemic there were significant concerns about antibody-dependent enhancement (8). Later, an analysis of the first 3082 patents within the EAP database provided evidence that associated early administration of high titer CCP to non-ventilated hospitalized patients with reduced mortality (9). Before the FDA granted emergency use authorization (EUA), the US EAP provided CCP to as many as 94,287 patients. During the past year, many studies employing either randomized controls (RCT) or propensity score-matched (PSM) controls have been published. RCTs and PSM studies reported so far have had largely opposite outcomes, with most but not all RCTs finding little overall effect on mortality while the PSM and many smaller trials reporting mortality benefits. Several RCTs did not have mortality as a primary endpoint or it was part of a composite endpoint (5, 10-12). These disparate results have led to confusion for both the public and the clinicians, leading to reduced enthusiasm for the use of CP, in part because RCT data is more influential in affecting the opinion of many physicians, specialty societies and government regulators.

As with any other medical treatment, several key factors should be taken into account when evaluating a trial, including the indication (which can be estimated by timing or clinical severity), the therapeutic dose and the intended outcomes. The choices made by the trial designers determine whether the trial will demonstrate or conceal clinical benefit. While much attention is appropriately focused on the performance features of clinical trials (sample size, fidelity to randomization, appropriate analysis), the biological rationale for the hypothesis being tested is critically important but not always taken into account.

Methods

On September 7, 2021, we searched PubMed (which is also indexing the medrXiv prepublishing server) for clinical trials of CCP in COVID19, focusing on RCTs and PSM studies only. Each study was analyzed for the following variables: NCT identifier, recruitment, randomization strategy, type of

control arm, baseline patient status, median neutralizing antibody (nAb) titer in both recipients (before CCP transfusion) and CCP units, type of viral neutralization test (VNT), primary endpoint, signals of efficacy, and reasons for failure

At the same date, the ClinicalTrials.gov database was searched for CCP RCTs worldwide having as status “completed”, “active, not yet recruiting” or “recruiting”.

Results

PubMed search retrieved 23 RCTs and 12 PSM studies about CCP, whose main variables are summarized in Tables 2 and 3. The characteristics of the VNTs used are summarized in Table 1. The variables were reconciled in 4 major topics, discussed in the following sections: the indication, the therapeutic doses, the relevance of CCP to the viral variant, and the intended outcome.

ClinicalTrials.gov search retrieved 8 CCP RCTs completed but not yet prepublished or published, 7 active but not yet recruiting RCTs, and 10 RCTs which are still recruiting (summarized in Table 4).

The indication

While it would be desirable to have a single drug that works at any disease stage, it was not reasonable to expect a silver bullet effect from neutralizing antibody-based treatments such as CCP in later stages of disease. COVID-19 is now well-defined as a disease with two stages, an initial viral phase characterized by flu-like and upper and lower respiratory symptoms, followed, in severe cases, by an inflammatory phase that is characterized by inflammation-driven damage to multiple organ systems, including the lungs that can impair gas exchange and cause life-threatening hypoxia and damage to multiple organs, including the brain and blood vessels (13). Specific intact antibodies in CCP are expected to neutralize SARS-CoV-2 in the intravascular system and, in some patients, prevent progression from early to severe and life-threatening disease (as seen in animal models (14)), but this antiviral therapy cannot be expected to reverse the inflammatory phase of the disease, nor neutralize infectious viruses invading the extravascular system. Thus, COVID-19 is similar to influenza, a disease in which antivirals are effective early in disease but have no effect in later stages when the symptomatology stems largely from the inflammatory response. The rationale for administering CCP as early as possible in the course of COVID-19 stems from the neutralization stoichiometry itself: the larger the number of actively replicating virions in the body, the higher the nAb dose needed for neutralization (15). Some uncontrolled studies have reported a lack of association between early intervention and outcomes (16, 17), but in these studies the level of neutralizing antibody (nAb) or the overall anti-Spike antibody level in the infused CCP was unknown, leaving room for alternative explanations.

At the beginning of the pandemic, some investigators and opinion leaders, riding the wave of CCP successes in anecdotal reports in the media and small case series, introduced CCP to the general public as a panacea for any patient with COVID-19, including life-threatening cases, leading to confusing messaging: after reports of failure in severely ill patients emerged, opinions became polarized and the debate became everything but scientific (18). In clinical trials, the indication (i.e., the

baseline clinical setting) has been variously defined by patient status (outpatient vs. presenting to the emergency room vs. hospitalized vs. ICU-admitted), disease severity (using 5-category COVID-19 Outpatient Ordinal Outcome Scale (19), a 6-category ordinal scale (12), a 7-category COVID-19 severity scale (20), the WHO 8- (21) or 11-category (22) ordinal scales, or pneumological scores such as SOFA), the time elapsed before recruitment (also variably defined as from molecular diagnosis, from onset of hospitalization, from diagnosis of pneumonia, or from onset of symptoms), or by serological status (presence of antibodies or the ability to neutralize SARS-CoV-2). This variability in inclusion criteria for studies has resulted in marked heterogeneity in recruited patients.

An additional complexity in recruitment to CCP trials is time to treatment. Clinical trials involve administrative requirements and consent procedures, and recruitment to a RCT further requires randomization, which may produce delays in treatment. CCP therapy requires matching on blood type, ordering the CCP, which may or may not be available on site, and setting up the transfusion. This inherent delay from randomization to infusion means that RCTs may build in a disadvantage for the CCP study arm, where controls may have received treatment earlier in the disease course (as, for example, in the CP3O trial (23). ABO-compatible CCP units may be not readily available at the local blood bank and recruited patients may have to wait for a compatible unit of CCP. These almost inevitable delays from randomization mean that CCP may be provided later in the illness than is ideal, and even if the trial intends to treat early, in practice it may not be possible.

During a pandemic, moreover, delays in treatment are magnified. The accrual of severely ill patients in emergency departments and the overwhelmed or even collapsed health care systems can create long delays from arrival in the emergency room to treatment. In the absence of quick (antigenic or molecular) tests for SARS-CoV-2, the turnaround time for final confirmation of diagnosis with PCR, which must often be run in batches, can take several hours. All of these factors are likely to impact the efficacy of CCP treatment. To shorten such time, fully screened CCP collected from eligible donors (24) could be safely administered within emergency departments shortly after admission and even before the patient reaches the ward.

The therapeutic dose

Determining the effective dose of CCP is difficult in a pandemic because the antibody assays and other tests needed to assess the potency of any antibody product take time to be developed. In practice, the effective dose is the product of multiple factors, none of which is fully standardized. The first factor is the concentration of the nAbs as measured by a VNT. At the beginning of the pandemic, only a few BSL3 (or higher)-equipped virology laboratories could run VNT using authentic live SARS-CoV-2 virus: the procedure was time-consuming (3-5 days) and the reports were operator-dependent. Nowadays, the availability of Spike-pseudotyped viruses which can be managed under the more widely available BSL-2 laboratories, or cell-free ACE-2 competition assays, combined with automated (e.g., luminescence-based) readings, have standardized outcomes and shortened turnaround times (25): however, harmonization between different assays is still a work in progress (26). The VNT differs according to the type of replication-competent cell line, the viral isolate used for the challenge (which

is critically important when the virus is mutating rapidly as has been the case with emergence of variants of concern), the multiplicity of infection (i.e., the ratio between the viral inoculum - referred with different measuring units – and the number of replication-competent cells within each well), the detection system (optic microscopy for cytopathic effect, immunostaining, quantitative PCR, or luminometer for engineered pseudoviruses), and finally the threshold of neutralization (50% or 90%). The DAWN-plasma RCT provides a clear example of such heterogeneity, with 4 different VNTs used in at different participating laboratories. It was not until August 2020, when many trials were already underway, that the FDA Emergency Use Authorization 26382 defined high-titer CCP on the basis of correlation with a reference standard, the Broad Institute the live-virus, 5-dilution VNT as a 50% inhibitory dilution (ID_{50}) of 1:250 or more (https://www.fda.gov/media/141481/download), and exclusive use of high-titer CCP was formally recommended by the FDA only on March 9, 2021.

Table 1 summarizes the key variables in VNT employed to date in CCP RCTs. Published trials have varied greatly in their approaches to antibody quantification whether in measured transfused CCP units or in recipients. Many trials have relied on high-throughput semi-quantitative or qualitative assays with a poor-to-moderate relationship with nAb titers. Although most trials performed a correlation analysis between VNT and high-throughput serological assays, in many cases the CCP units were tested only with the latter without validation, as was the case with 66% of the patients in the PlasmAR trial (12). This procedure risks an incorrect evaluation of the neutralizing CCP activity. Another cause for discrepancies in outcomes could be that although IgM, IgG, and IgA are all capable of mediating neutralization, VNT titers correlate better with binding levels of IgM and IgA_1 than they do with IgG (27). Yet it is IgG that is routinely measured in high-throughput serological assays, and these assays include non-neutralizing IgGs, the role of which in activity against SARS-CoV-2 has not been established. Trials should preferentially use VNTs to assess serostatus of transfused units and not rely on high-throughput serology.

As for any other medicinal product, CCP exhibits a dose-response relationship, which is also evident when using high-throughput assays. In the subgroup analysis of the EAP, a gradient of mortality was seen in relation to IgG antibody levels in the transfused CCP. In the subgroup of patients who were not receiving mechanical ventilation, death within 30 days after CCP transfusion occurred in 81 of 365 patients (22.2%; 95% CI, 18.2 to 26.7) in the low titer group, 251 of 1297 patients (19.4%; 95% CI, 17.3 to 21.6) in the medium-titer group, and 50 of 352 patients (14.2%; 95% CI, 10.9 to 18.2) in the high-titer group. Depending on the statistical model, the RR for 30-day mortality in high-titer CCP compared to low-titer CCP recipients ranged from 0.64 – 0.67, with an upper 95% confidence bound of 0.91 (8). Similarly, the large retrospective PSM study from HCA reported a 0.2% decreased risk of mortality for every 1 unit of S/Co serology level (28).

The nAb titer (or total IgG levels as measured by surrogate assays) only describes one factor involved in defining the real therapeutic dose in that it represents the concentration of just one (likely the main) active ingredient. But CCP contains additional antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC), complement activation and phagocytosis of viral particles, functions that can each contribute to its antiviral effects (29). At this time the relative importance of nAbs vs. the other

antibody activities is not understood, but, hopefully, retrospective analyses that correlate CCP efficacy with these activities will reveal additional variables that need to be considered in choosing optimal CCP units.

Despite these uncertainties, we can make estimates of likely effective doses based on the available clinical experience thus far. The therapeutic dose of nAb is a product of its concentration in the infused CP multiplied by the overall infused CP volume, adjusted to the recipient body weight to take account of dilution into the blood volume and tissues. RCTs have varied in the provision of volume per unit (200-300 ml), and most importantly in cumulative volume per patient (1-4 units) and in extent of exposure to diverse antibodies from various CCP donors, and no published trials have adjusted levels of nAbs by recipient body weight (or, when attempts have been performed, they referred to the old-fashioned 10-15 ml/kg dose inferred from treatment of hemorrhagic coagulopathies (30)). A failure of CCP to improve outcomes when 200-ml of 1:160 nAb-titer CCP is provided to a patient who weighs 120 kg represents quite a different scenario from failure of a 600-ml transfusion of 1:640 nAb-titer CCP to produce improvement in a 60-kg patient. But these central issues in dosage have not been considered in the RCTs published so far.

Several RCTs performed nAb titration, but with highly heterogenous methods which makes comparability of doses across studies difficult. Table 1 attempts to reconcile doses across those trials, showing that they actually differed more than was apparent by inspection of raw titers. The lack of utility from low-titer (1:40) CCP in moderate COVID-19 was confirmed by the PLACID trial (10). As long as a clear therapeutic dose is not identified, it seems prudent to transfuse units containing nAb titers at least 10-fold higher than the nAb titer measured before transfusion in recipient serum. Similarly, the ConCOVID RCT showed that CCP units having nAb titers similar to those of the recipients (1:160) did not confer a clinical benefit (31). CCP units with an adequate nAb titer (nowadays estimated at $\geq$1:160) are more easily found among older males who recovered from a previous symptomatic COVID-19 requiring hospitalization (32, 33): unfortunately, such donors were poorly represented in the first donation waves, which tended to obtain CCP from younger donors will mild disease, and, presumably lower nAb titers (10).

Relevance of CCP to the viral variant

Albeit not formally demonstrated, CCP manufactured by pooling ABO-matched transfusion from many different donors (e.g., in PlasmAr (12)) theoretically have greater polyclonality of nAbs than repeated CCP doses from a single-donor (e.g. CAPSID (34)) and should grant higher efficacy against viral variants. Nevertheless, pooling typically occurs among donors attending the same blood bank, making donor exposure to different viral variants unlikely.

An analysis of potential variables associated with CCP efficacy associated near-sourcing with reduced mortality, with the efficacy of CCP in reducing mortality falling sharply when the CCP source was more than 150 miles from where it was used (35). This finding suggests that SARS-CoV-2 viruses vary enough in their antigenic composition in different geographic locations to create antibody

responses that differ by locale (36). Even though CCP is often standardized for nAb titer to the Spike protein, the VNT could use a nonrelevant viral strain, or miss major functional differences for the antibody response (29). This finding has implication for RCTs that use nationally sourced (centralized) CCP, since the attempt to standardize the therapeutic units centrally could inadvertently reduce CCP efficacy if hospitals use CCP obtained from distant loci. For example, in the C3PO RCT, which was conducted in 21 USA states, 95% of the donor CCP was collected in either Chicago or Denver: since only 4 of the 48 centers were in Illinois or Colorado, most CCP usage had to be from remote sources (23). By contrast, the NCT04359810 RCT in New York and Brazil used CCP locally sourced in New York, whose efficacy against P.1 was tested to ensure efficacy at the other recruiting center in Brazil (11).

Although also not formally demonstrated during clinical trials, it is also reasonable to assume that CCP collected during early pandemic waves could be less effective against currently circulating variants of concern (37). RCTs whose recruitment was protracted across multiple pandemic waves (e.g., ConPlas-19 and TSUNAMI) and which relied on CCP collected and banked months earlier could have inadvertently used CCP with reduced activity against the SARS-CoV-2 strains circulating the community when the therapy was administered. Hence, both geography and time of collection of the CCP are important variables when considering the efficacy of the treatment.

The intended outcomes

Most trials (CONTAIN, COMPILE, and PassItOn being exceptions) have used composite endpoints or specialty scores (e.g., SOFA) rather than progression in the simple WHO ordinal scale or mortality, and many were stopped because of apparent futility at a time when they may have been underpowered to detect significant benefit. As represented in Figure 1, several studies have reported overall negative results (panel A) despite the presence of positive signals of efficacy just barely missing statistical significance (panels B and C). The significance level (i.e., p= 0.05) is largely a socially constructed convention for rejecting the null hypotheses, but it has often been misinterpreted as a measure of reality by many individuals not familiar with the nuances of statistics. For example, some CCP studies have concluded that a difference that did not achieve a p value < 0.05 was an absence of difference, even when mortality in the CCP arm was ~20-40% lower than in controls. This reasoning played a central role in the polarized views of CCP efficacy and prevented subsequent studies to drill down on positive effects that were observed. The dogged pursuit of statistical significance, viewed as a measure of reality instead of the actual reality demonstrated by the data, during a public health emergency dealt a serious blow to studies of CCP and created significant confusion for clinicians. It is also important to understand that RCTs are powered to be less tolerant of Type I error than Type II error, which are conventionally set at .05 and .20, meaning that a Type II error is expected four times as often as a Type 1 error. This statistical convention can contribute to the absence of significance in studies that were set up early in the pandemic when there was little information on expected effects for the various patient populations studied and the patients were very heterogenous such that only subgroups may have responded. Many studies were originally designed

to enroll patients at any disease stage, and it should be no surprise that subgroup analyses on the groups that were later demonstrated more likely to benefit from CCP (e.g., early treated, seronegative patients, those receiving high nAb titre) were underpowered to reach statistical significance, as shown by orange color predominance in panel C of Figure 2. Nevertheless, favorable trends are a shared feature across such trials. Lastly, rigid adherence to primary outcomes that were often fixed in the early days of the pandemic when information about disease stage and quality of CCP associated with efficacy were not understood. When these outcomes were not met, trials were considered failures even though there were often signals of efficacy in the data that were not considered as valuable since these had not been pre-specified, even when they made biological sense. For example, in the New York-Brazil RCT cited above, CCP did not lower the primary end-point of clinical status on an ordinal scale, but the statistically significant halving of mortality was acknowledged in the abstract. Would it have made sense to ignore the strong effect of CCP on mortality in this trial just because mortality was not selected as a primary outcome? Although we agree that subgroup analysis carries the risk of 'cherry picking' data, such analyses are often important for hypothesis generation and critically important during the emergency of a pandemic where neither viral pathogenesis nor therapeutic variables are well understood. When sub-group analyses are based on firm biological principles, such as focusing on those treated early in disease or lacking their own serological response, the exercise is not cherry picking. To emphasize this point, Christopher Columbus missed the pre-specified primary endpoint of his mission - reaching India - but no one considers his discovery of the New World to be a failure! Turning to the clinical arena, most trials of anticoagulants in myocardial infarction found reductions in mortality of about 20-25%, which was generally not significant in these underpowered trials that declared the findings to be null, even though such a mortality reduction would clearly be of value (38).

Another misunderstood endpoint is viral clearance, defined as the conversion of nasopharyngeal swabs (NPS) from positive to negative for PCR evidence of SARS-CoV-2 in CCP-treated patients. While there was early and robust evidence for this effect from CCP (4, 10), some RCTs (e.g., TSUNAMI) failed to find differences between arms just because they sampled NPS too late after CCP treatment, when the endogenous immune response had also mounted in the control arm, and differences vanished.

Analyzing failures in individual RCTs.

We use the word 'failures' with care and considerable nuance, since negative trials can be very important in teaching us about populations that do not benefit from CCP or variables that affect its efficacy. Keeping the factors discussed above in mind, we have analyzed individual RCTs in detail. At the very beginning, many historically or internally controlled observational studies showed clinical benefit from CCP and this led the FDA to issue an EAP in March 2020 that was converted into an emergency use authorization (EUA) in August 23, 2020. The largest observational study is the US open-label EAP (NCT04338360) led from Joyner *et al*, which enrolled 105,717 hospitalized patients

with severe or life-threatening COVID-19 from April 3 to August 23, 2020 (39). In an analysis of the effect of antibody in CCP performed independently of the results cited above (8) and using a nAb titer in an overlapping but non-identical group of EAP patients, the FDA showed that the 7-day mortality in non-intubated patients who were younger than 80 years of age and were treated within 72 hours after diagnosis was 6.3% in those receiving high-titer CCP and 11.3% in those receiving low-titer CCP (https://www.fda.gov/media/142386/download).

In a later analysis of a larger (N = 35,322) subset of EAP patients, (including 52.3% in the intensive care unit (ICU) and 27.5% receiving mechanical ventilation), the 7-day mortality rate was 8.7% in patients transfused within 3 days of diagnosis but 11.9% in patients transfused ≥4 days after diagnosis. Similar findings again from the US EAP were observed in 30-day mortality (21.6% vs. 26.7%) (40). The major criticism of these results is that controls were neither randomized nor PSM: hence a difference in the treatment outcome between treated and untreated groups may be caused by a factor that predicts treatment rather than by the treatment itself. However, importantly, nAb titer analysis was retrospectively done, both patients and physicians were unaware of the nAb content in the CCP units used, the results are what would have been expected from the experience with antibody therapy, and multivariate models were used to adjust for potential confounders (1). Additionally, given the outline of an optimal use case with this data and the earlier underpowered RCT by Li *et al* (5), it is unfortunate that due to (a) lack of awareness and (b) logistical burden associated with protocol adjustments, involving repowering and new patients' recruitment criteria, later treatment RCTs either continued or initiated without modifications to include newly available evidence.

The highest level of scientific evidence in primary clinical research stems from prospective PSM and RCTs. PSM studies (Table 3) balance treatment and control groups on a large number of covariates without losing a large number of observations. Unfortunately, no PSM study to date has investigated nAb titers by VNT, and all times have been reported since hospitalization (excluding outpatients). Nevertheless, in 2 retrospective PSM studies from 2 different hospitals in New York, trends for improved outcomes in non-intubated and those treated within 7 days since hospitalization (HR 0.33) were observed (41, 42). These findings were later confirmed in a prospective PSM study from Houston (43, 44). Of interest, a retrospective PSM study from Providence did not show any benefit, but patients were treated at a median of 7 days after onset of symptoms (45). Another PSM study from Yale associated CCP with a 35% reduction in mortality (46). That study is notable in that it included patients on mechanical ventilation who would not normally be expected to benefit from CCP and the percentage of individuals receiving corticosteroids was very low since the study was conducted in the early days of the pandemic in the USA. Another PSM from the Washington DC area found a reduction in mortality with CCP use at both days 14 and 28, which reached statistical significance at the earlier date (47). Finally, a very large study from 176 community hospitals affiliated with Healthcare Corporation of America confirmed substantial mortality reduction in hospitalized patients receiving CCP within 3 days from admission (48).

Since PSM only accounts for observed (and observable) covariates, and not latent characteristics, RCT remains the gold standard for highest-level evidence (Table 2). In the PlasmAr RCT, the small

number of early arrivals (less than 72 hours) showed superior primary and secondary outcomes in the CCP arm (n= 28) compared to the placebo arm (n=11), but the minimal contribution of this group to the overall cohort (228 CCP and 105 placebo) made the advantage disappear in the final outcomes at day 30 (12). In another Argentinean RCT on 160 outpatients older than 65 years of age with mild COVID-19 who were treated with CCP within 72 hours, progression to severe COVID-19 halved at day 30 (49). An RCT from India reported that patients younger than 67 treated at a median of 4 days after hospital admission manifested superior mitigation of hypoxia and survival in the CCP arm (50). Another RCT in Spain enrolling patients at less than 7 days of hospitalization showed four deaths in the control arm, none in the CCP arm (51). Given that conventional peer-review slows down during a pandemic, pre-publishing RCT results by the preprint mechanism should be encouraged to accelerate sharing of potentially life-saving therapeutic approaches and to provide pre-publication review that could improve the quality of the final published study.

Figure 1 graphically places the outcomes of RCTs and PSM studies on a Cartesian plot having timeliness and nAbs dose as variables (if values are disclosed in the reports): this makes immediately clear that the few successes at reaching the primary endpoints have gathered into the lower right corner (high nAb dose and early intervention), while the many “failures” have been scattered all around (panel A), reflecting lower antibody levels infused or late treatment, or both, with the latter being the commoner problem. Nevertheless, when we focus on mortality irrespective of statistical significance (panel B) or focusing on statistical significance (panel C), many more RCTs showed clear benefits.

We will focus here on “failures” as identified by title, abstract and/or press recognition. Narratively, we could group so-called “failures”, with failure implying inability to demonstrate a favorable outcome to CCP use, into 4 categories, according to the main reasons:

1. Trials that transfused insufficient therapeutic doses of CCP due to either low total IgG levels or low nAb levels (e.g., PLACID)
2. Trials that transfused appropriate doses of CCP but too late, but which nevertheless reported signals of efficacy (e.g., RECOVERY, CAPSID, NCT04359810 and TSUNAMI)
3. Trials that were stopped too early to observe benefit or with inherent design flaws, and/or were underpowered such that likelihood of success was reduced (e.g., C3PO)
4. Trial in which CCP was used to treat a condition not amenable to antibody intervention, such as hypoxia that is caused by pulmonary inflammation (e.g., COP20)

Stopping trials for futility is an occurrence that deserves special attention, because it represents wasted resources during a pandemic. Six RCTs so far have been halted for futility, namely RECOVERY, REMAP-CAP, CONCOR-1, C3PO, NCT04361253, and COP20, with the first one being to date the strongest evidence for futility (30), with its massive recruitment affecting the outcomes of systematic reviews (52). Instead of stopping trials for futility based on pre-set endpoints it makes more sense that DSMBs facing a high likelihood of lack of statistical significance provide advice on trial modifications that are likely to amplify the significance of signals of efficacy evident in these studies.

This would seem a more responsible action than trial cessation given the paucity of therapeutic alternatives in the pandemic emergency. Indeed, a Bayesian re-analysis of RECOVERY data with a wide variety of priors (vague, optimistic, skeptical and pessimistic) calculated the posterior probability for both any benefit or a modest benefit (number needed to treat of 100). Across all patients, when analyzed with a vague prior, the likelihood of any benefit or a modest benefit was estimated to be 64% and 18% respectively. In contrast, in the seronegative subgroup, the likelihood of any benefit or a modest benefit was estimated to be 90% and 74% (53). This finding of benefit accruing to specific sub-groups, who were not determined post-hoc but because they were likely to benefit based on understanding of principles of CP treatment is found in nearly every trial whose overall finding is negative.

The inadequacy of meta-analyses.

With all the heterogeneity in key drivers discussed in the former paragraphs, it becomes clear that secondary research (ranging from umbrella reviews to meta-analyses to systematic reviews), whereby each study is considered at the same level, invariably ends up with biased and divergent conclusions. This adds confusion to the already complex field of individual trial outcomes. Amazingly, as of August 24, 2021, PubMed has indexed 25 meta-analyses on CCP efficacy, more than the RCTs reported at the same date. Until the beginning of 2021, meta-analyses (variably including observational studies) were generally in favor of CCP (54), but began to be biased towards failure after publication of the large RECOVERY trial (30), which, by enrolling as many as 11,448 patients, diluted all the other divergent RCTs. Clear examples of this phenomenon come from a widely cited metanalysis from Janiaud *et al* in *JAMA* (52) which included press release data from RECOVERY and from the living systematic review by the Cochrane Group (55). This paper was surely unprecedented in the tradition of meta-analysis, not only because it included a study based only on a news release (which proved to differ in some important respects from the published paper), but because it allowed these data from a news release to dominate the entire analysis. Several groups attempted to dissect the RECOVERY trial and others by running subgroup analyses in their systematic reviews (53, 56, 57), but these reviews were unable to restore confidence in CCP efficacy in the clinical community that had been lost because of the publication of the overall negative findings of RECOVERY and PlasmAr (58). A metanalysis of 22,591 patients (enrolled in 10 RCTs and 15 observational studies) showed that early CCP significantly reduced mortality (RR 0.72, $p<0.00001$), but only in patients who were not suffering severe or critical disease (59). On the other hand, another metanalysis of 18 peer-review clinical trials, 3 preprints, and 26 observational studies actually found that CCP use was associated with reduced risk of all-cause mortality in severe or critical COVID-19 patients (60). A recent umbrella review of 29 metanalyses and systematic reviews found evidences for improvement in the CCP arms for some outcomes (overall mortality, viral clearance at day 3,) but not for others (clinical improvement, length of hospital stay (61).

Rather than pooling published RCTs, the Continuous Monitoring of Pooled International Trials of Convalescent Plasma for COVID-19 Hospitalized Patients (COMPILE) study pooled individual patient data from ongoing RCTs at two-week intervals. Unfortunately, with the single exception of CONTAIN, participating RCTs largely shared late usage (DAWN-plasma, PLACID, ConCOVID, ConPlas-19, NCT04421404, NCT04397757, and the Brasília Covid-19 Convalescent Plasma (BCCP)) (62).

Conclusions

While CCP contains a plethora of biologically active molecules (63), we now have very strong evidence that appropriately vetted CCP from eligible convalescent donors is safe for patients (64, 65), with no evidence of increased risks of transfusion-transmitted acute lung injury, antibody-mediated enhancement concerns feared in the early days of the pandemic (66) nor is there evidence that CCP induces accelerated SARS-CoV-2 evolution (11). Polyclonal antibodies such as CCP, or CCP-derived hyperimmune globulins made from large donor pools, are likely to offer better protection against onset of variants than monoclonal antibodies. Outcomes in immunocompromised patients treated with CCP have been successful in the long-term, with minimal evidence for immune escape (67). There is evidence that vaccinated convalescents may have even higher nAb titers than unvaccinated convalescents offering the promise of expanded success in using CCP (68).

We have also learned that CCP is less likely to benefit patients requiring oxygen (i.e., from level 4 and up on the 11-point WHO ordinal scale), and hence, ideally, the focus should be on outpatients and in identifying that subset of patients who seek hospital care and are still sufficiently early in the course of disease such that they can benefit from CCP. This finding parallels the finding with hyperimmune serum and anti-Spike monoclonal antibodies, which at first failed in hospitalized patients (69, 70), but later succeeded for ambulatory patients with mild to moderate COVID-19 (71) and were approved for emergency use. However, at this moment clinical use in the US is restricted by the FDA to inpatients.

CCP usage per admission peaked after issuance of the EUA, with more than 40% of inpatients estimated to have received CCP between late September and early November 2020. However, following reports of RCTs that failed to show clear benefit from CCP, usage per admissions declined steadily to a nadir of less than 10% in March 2021. A strong inverse correlation (Pearson correlation coefficient of -0.5176 with $P = 0.00242$) was found between CCP usage/hospital admission and deaths occurring 2 weeks after admission, and this finding was robust to examination of deaths taking place 1, 2 or 3 weeks after admission. Changes in the number of hospital admissions, prevalence of variants, and age of patients could not explain these findings. The authors estimated that the retreat from CCP usage, a phenomenon they termed “plasma hesitancy”, might have resulted in 29,000 to 36,000 excess deaths in the period from mid-November 2020 to February 2021 (72). The same analysis estimated that USA had avoided 96,000 excess deaths from August 2020 to March 2021 by its liberal deployment of CCP.

Several lines of evidence, ranging from the EAP to clinical trials employing RCT or PSM controls are now indicating how CCP should be used in immunocompetent patients (73). The evidence supports the initiation of CCP treatment as early as 44-72 hours within onset of symptoms (which largely

pertains to outpatients) and using CCP with a nAb titer > 1:160. Benefit within 1 week from onset of symptoms (including in hospitalized patients) is less well understood, although a benefit from higher therapeutic doses cannot be ruled out at this stage. Clinical benefit seems absent when administered after 1 week from onset of symptoms or in patients requiring ventilation, or in those who receive CCP with a low nAb titer. Nevertheless, chronically immunosuppressed patients benefit from CCP even at later stages (67, 74, 75) : the best evidence for this scenario comes from a prospective PSM showing a halving of mortality in ICU-admitted oncohematological COVID-19 patients who received CCP (76). We note that while there have been concerns that use in immuncompromised can promote the emergence of antibody-resistant variants, such variants have emerged from massive replication in susceptible populations and not from treated patients, who in any case are isolated in hospitals where mitigation efforts to reduce transmission are employed, and are thus very unlikely to transmit their viruses further (77). Such simple concepts have been poorly communicated to the general public and the clinical community, who should be better informed of the state of current evidence that support CCP efficacy.

The future of CCP

CCP remains a relatively inexpensive therapy that is available throughout the world even in resource poor areas that cannot afford expensive antiviral drugs or monoclonal antibody therapies. Much has been learned about the variables that affect CCP efficacy even though, as recounted here, the clinical efficacy data is mixed. Table 4 lists the RCTs whose outcomes have still to be reported after completion or which are still recruiting patients. Unfortunately, little new can be expected given that most of these RCTs were designed to enroll patients having symptoms for more than 7 days. Given the heterogeneity of the product and the complex variables that contribute to efficacy it is remarkable that many studies have reported reductions in mortality. This suggests a robust therapeutic effect that allow signals of efficacy to break through all the noise imposed by variability in the product and its clinical use. The positive evidence for CCP efficacy cannot be dismissed while negative results can be explained. In the absence of good therapeutic options for COVID-19, CCP is likely to find a niche in the early treatment of disease. Instead of looking for unlikely superiority outcomes, noninferiority RCTs comparing monoclonal antibody versus CCP in early arrivals should be initiated. Such an RCT is very unlikely to be sponsored by vendor companies, so public institutions should be sensitized to funding it.

Given the experience accumulated with COVID-19, it is almost certain that CP will again be deployed for the next epidemic and we are hopeful that lessons learned in this pandemic are heeded such that use and trials focus on the very early use with high-titer CP.

We declare we have no conflict of interest to disclose.

Figure 1

Simplified graphical representation of CCP RCTs reported to date, plotted according to earliness of intervention and nAb titers in CCP. In **panel A**, green text indicates trials which met the primary endpoint with statistical significance; orange text indicates trials which failed to meet the primary endpoint but showed statistically nonsignificant trends in favor of CCP; red text indicates trials which failed to show and benefit from CCP in the primary endpoint. In **panel B**, green text indicates trials which showed overall mortality benefit from CCP; orange text indicates trials which showed mortality benefit from CCP in the subgroup of early arrivals or higher nAb titers; red text indicates trials which failed to show any mortality benefit from CCP. In **panel C**, green text indicates trials which showed statistically significant mortality benefit from CCP (overall or in the subgroup of early arrivals or higher nAb titers); orange text indicates trials which showed statistical trends towards mortality benefit from CCP (overall or in the subgroup of early arrivals); red text indicates trials which failed to show any mortality benefit trend from CCP in any subgroup. Underlined text indicates large trials which were not RCT and for which nAb levels was inferred from high-throughput serology, but are nevertheless reported as reference studies. Numbers in parenthesis indicate cumulative number of patients enrolled.


A
B
C
median days from onset of symptom or diagnosis to randomization
nAb titer (actual or estimated)
0
3
6
9
1:40
1:80
1:160
1:320
1:640
Gonzalez, medrXiv
ConCOVID, Nat Commun
PLACOVID, Eur Resp J
Bennett-Guerrero, Crit Care Med
RECOVERY, Lancet
O'Donnell, J Clin Invest
PlasmAr, NEJM
DAWN-plasma, Eur Resp J
ConPlas-19, J Clin Invest
CAPSID, J Clin Invest
PLACID, BMJ
TSUNAMI, JAMA Network Open
COP20, BMC Res Notes
C3PO, NEJM
Egloff US HCA, J Clin Invest
Joyner US EAP, NEJM
Libster, NEJM

518

519

Table 1

Details of viral neutralization tests (VNT) employed in CCP RCTs. Information was retrieved from original article (including Supplementary Appendix). Whenever not reported, the corresponding author was contacted (marked with *). If the details could not be retrieved the field is labelled “n.a.” (not available). IC: inhibitory concentration. NT: neutralization titer. PFU: plaque-forming unit.

	RCT	cell line	cells seeded per well	virus lineage	virus per well	multiplicity of infection (MOI)	length of incubation	assay read-out	threshold	protocol reference
authentic live SARS-CoV-2	NeuCoV-NET NCT04393727 (TSUNAMI)	Vero E6	12,000	SARS-CoV-2/Human/ITA/PAVIA10734/2020 (D614G)	100 $TCID_{50}$	0.01	until the cytopathic effect (CPE) became evident.	CPE	last serum dilution that inhibited SARS-CoV-2 CPE by 90%.	(78)
	NCT04433910 (CAPSID)	Vero E6	n.a.	n.a.	100 PFU	n.a.	3 days	CPE	$PRNT_{50}$	(79)
	Broad Institute on a high throughput platform (BROAD PRNT). Part of NCT04355767 (C3PO)	Vero E6-TMPRSS2	10,000	SARS-CoV-2 live virus (D614)	n.a.	n.a.	48 hours	N-protein ELISA	samples whose curves lay above 0.5 for all the data points were considered non-neutralizing, with ID_{50}=20, while samples whose curves fell below 0.5 were considered highly neutralizing and assigned an ID_{50}=10,240.	(80)
	NCT04359810	Vero E6	10,000	2019-nCoV/USA-WA1-2020	100 $TCID_{50}$	0.01	48 hours	Triplex CII-SARS-CoV-2 rRT-PCR Test, EUA200510).	the highest CCP dilution that prevented virus growth (cycle threshold [Ct] was rated as neutralization titer.	(11)

	NCT04342182 (ConCOVID)	Vero-E6	n.a.	German isolate (GISAID ID EPI_ISL 406862)	400 PFU	n.a.	8 hours	CTL ImmunoSpot Image Analyzer	reciprocal of the highest dilution resulting in a reduction >50% of infected cells ($PRNT_{50}$)	(31)
	NCT04429854 (DAWN-plasma)	Vero E6	n.a.	BetaCov/Belgium/Sart-Tilman/2020/1	100 $TCID_{50}$	n.a.	5 days	CPE	$PRNT_{50}$	(81)
			18,000	2019-nCoV-Italy-INMI1	3 $TCID_{50}$	n.a.				(82)
			n.a.	Belgium/GHB-03021/2020	400 PFU	n.a.	4 days			(83)
			20,000	Belgium/S1871/2020	100 $TCID_{50}$	n.a.	2 days	anti-N staining	NT_{50}	(84, 85)
Spike pseudotyped viruses	Vitalant Research Institute (VRI) Pseudovirus Neutralization Part of NCT04355767 (C3PO)	ACE2 and TMPRSS2 expressing HEK293T cells	n.a.	VSV pseudotyped with Wuhan-Hu-1 Spike (D614G mutation and without 21 C-terminal aa)	n.a.	n.a.	18-24 hours	chemiluminescence reader	NT were calculated as a percentage of no-serum control and the NT_{50} was estimated from the dilution curve	(80)
	NCT04383535 (PlasmAr)	Vero-CCL81	20,000	VSV pseudotyped with Spike (CoV2pp)	n.a.	n.a.	18-22 hours	luminometer	IC_{50} is calculated as the midway point between the upper and lower plateaus of the curve. $absIC_{80}$ appeared to be a more	(86)

				and carrying *Renilla* luciferase gene in place of its G glycoprotein (VSVΔG-rLuc).					stringent measure of nAb activity, as some sera that have respectable MN absIC_{50} titers never achieve an absIC_{80}: this is due in part to the difference in the dynamic ranges between a luciferase-based assay (≥3 logs RLUs) and a MN assay (~1.5-log optical density [OD] values corresponding to the amount of viral protein detected).	
	CTRI/2020/04/024775 (PLACID)	Vero CCL-81 293 T/ACE2 cells	10,000	SARS-CoV-2 strain NIV2020770	n.a.	n.a.	36 hours	luminometer	n.a.	(87)
	NCT04345523 (ConPlas-19)	Vero E6	5,000	lentivirus pseudotyped with Spike and luciferase	titrated at 10 ng p24 Gag	n.a.	48 hours	luminometer	ID_{50} expressed as the highest dilution of plasma (reciprocal dilution), which resulted in a 50% reduction of luciferase activity compared to control without serum. Sigmoid curves were generated and ID_{50} neutralization titers (NT_{50}) were calculated by non-linear regression	(20)
	NCT04375098	n.a.	n.a.	HIV-1–SΔ19 pseudotyped with Spike and luciferase	n.a.	n.a.	n.a.	luminometer	samples with a neutralizing activity of at least 50% at a 1:160 dilution were considered positive and used to perform titration curves and ID_{50} NT calculations	(88)

	NCT04344535	n.a.	n.a.	PRNT and pseudovirus	n.a.	n.a.	n.a.	n.a.	n.a.	(89)
	NCT04600440	Vero E6	10,000	pseudovirus	200 PFU	n.a.	8 hours	Indirect immunofluorescence measured by TROPHOS Plate RUNNER HD®	number of infected cells were quantified and normalized to virus incubated without plasma. IC_{50} values were calculated using normalized data and a non-linear fit with variable slope.	(90)

Table 2

Randomized controlled trials (RCT) of COVID-19 convalescent plasma (CCP) reported to date. nAb: neutralizing antibodies. BSC: best supportive care. FFP: fresh frozen (nonconvalescent) plasma. n.a.: not assessed (i.e. antivirus antibodies were assessed only using high-throughput serology). IQR: interquartile range.

RCT identifier (acronym)	**recruitment (out of expected) (randomization strategy)**	**control arm**	**median days before randomization**	**baseline recipient 8-point WHO score*** (21)	**transfused CCP volume (ml)**	**median nAb titer in CCP units**	**median pretransfusion nAb titer in recipient**	**main outcomes reported in abstract or conclusions**	**likely reason(s) for failure**	**signals of efficacy**	**ref**
NCT04479163	160 (out of 210) (1:1)	normal saline	39.6 hours (from symptoms; and > 65 yrs)	3	250	n.a.	n.a.	progression to severe COVID-19 halved at day 30	no failure	-	(49)
BKH-CT-012	49 (1:1)	BSC	< 3 (from RCU admission)	5	400	n.a.	n.a.	duration of infection reduced by 4 days; mortality 1/21 in CCP arm vs 8/28	no failure	-	(91)
CTRI/2020/05/025209	80 (1:1)	BSC	4.2 (from hospital admission)	5	200+200	n.a.	n.a.	immediate mitigation of hypoxia, reduction in hospital stay as well as survival benefit was recorded in severe COVID-19 patients with ARDS aged less than 67 years	no failure	-	(50)
ChiCTR20	103 (out of	BSC	30 (from	5-6	200	n.a.	n.a.	no significant	moderately late usage	reduced mortality at day 28	(5)

00029757	200) (1:1)		symptoms)					difference in 28-day mortality (15.7% vs 24.0%) or time from randomization to day-28 discharge (51.0% vs 36.0%)		only in WHO score 5 patients (HR 2.5); negative conversion rate of viral PCR at 72 hours in 87.2% of the CCP group vs 37.5% of the control group (OR, 11.39)	
NCT04342182 (ConCOVID)	86 (out of 426) (1:1)	BSC	10 from symptoms; 2 from hospitalization	5-6	300	1:320 ($PRNT_{50}$)	1:160 in 79% of recipients	no benefit at day 15	very late usage, high rate of seropositives	none	(31)
CTRI/2020/04/024775 (PLACID)	464 (1:1)	BSC	6 (from symptoms)	4-5	200+200	1:40	1:90	no benefit at day 28	moderately late usage; high rate of seropositives; extremely low nAb titre in CCP	none	(10)
NCT04345523 (ConPlas-19)	350 (1:1)	BSC	8 (from symptoms)	3 (25%) 4 (75%)	250-300	1:292	n.a.	no significant differences in primary endpoint (proportion of patients in categories 5, 6 or 7 (death) at 14 days	underpowered for mortality; primary endpoint set at just 15 days	primary endpoint significant at day +28. Trends for reduced overall mortality (p = 0.087) at day +28, expecially in aged > 75 years	(51)
NCT04375098	58 (1:1)	late CCP	6 (from symptoms)	3-4	200+200	≥ 1:160	59% < 1:160 (16% of patients enrolled before day 5 were ≥1:160 vs 60% of those	no benefit at day 30 in death, mechanical ventilation or prolonged hospitalization compared to CCP administration only in case of clinical worsening or > 7	underpowered, moderately late usage	none	(92)

							enrolled after day 6	days after enrolment			
NCT04383535 (PlasmAr)	333 (2:1)	normal saline	8 (from symptoms)	5	500	1:300 IC_{80}	n.a.	no benefit at day 30 (16.2% vs. 31.2%)	moderately late usage	early arrivals (less than 72 hours) showed superior primary and secondary outcomes in the CCP arm (n= 28) compared to the placebo arm (n=11), but the minimal contribution of this group to the overall cohort (228 CCP and 105 placebo) made the advantage disappear in the final outcomes at day 30 (12).	(12)
NCT04356534	40 (1:1)	BSC	n.a.	4 (95%) 5 (5%)	200+200	n.a.	n.a.	no difference in requirement for ventilation, white blood cell count, LDH, C-reactive protein (CRP), troponin, ferritin, D-dimer, procalcitonin, mortality rate at 28 days	underpowered; the CP group were a higher risk group with higher ferritin levels	primary outcome measure – ventilation – was required in 6 controls and 4 patients on CCP (risk ratio 0.67 95% CI 0.22 – 2.0, p=0.72); mean time on ventilation was 10.5 days in the control against 8.2 days in patients on CCP (p=0.81).	(93)
NCT04346446	29 (1:1)	FFP	< 3 (from symptoms)	4-5	250+250	n.a.	n.a.	no significant reduction in mortality or hospitalization	nAb measured with surrogate competitive assay (GenScript); beneficial factors in FFP used in control arm (63)	better median improvement in PaO_2/FiO_2 at 48-hours [42 vs 231] and at day 7	(94)
NCT04381936	11558 (1:1)	BSC	9 from symptoms; 2	4-7	275±75 (81% 2	n.a.	83% seronegati	no significant difference in 28-day	late usage	the risk ratio for patients randomized within 7 days of	(30)

(RECOVERY)			from hospitalization		units from different donors; 12%1 unit)		ve	mortality, progression to invasive mechanical ventilation. Closed for futility		symptom onset was 0.92 in favor of CCP versus 1.06 in patients randomized later. A reanalysis of seronegative patients (having 10% lower mortality) with a vague prior found that the likelihood of any or modest benefit was 90-74% (53).	
NCT04348656 (CONCOR-1)	614 (out of 1200)	n.a.	8 from symptoms	4-6	500 ml (within 12 hrs if from 2 different donors	n.a.	n.a.	closed for futility (even in the subgroup transfused within 3 days)	moderately late usage	each standard log increase in neutralization or ADCC independently reduced the potential harmful effect of CCP (OR=0.74), while anti-Spike IgG increased it (OR=1.53)	(95, 96)
NCT02735707 (REMAP-CAP)	1084 (out of 7100?)	n.a.	≤ 3 from ICU hospitalization	5-6	1-2 units	n.a.	n.a.	no significant difference in organ support-free days at day 21 or in-hospital mortality. Closed for futility	very late usage	none	(97, 98)
NCT04355767 (C3PO)	511 (out of 900) with at least 1 risk factor associated with severe COVID-19	n.a.	4 from symptoms, presented to the emergency department	n.a.	1 250-ml unit	1:641 ID_{50}	n.a.	nonsignificant difference in risk difference (1.9%). Outcomes regarding worst illness severity and hospital-free days were similar in the two groups	'all cause' outcome instead of COVID-19-related outcome; centralized CCP supply to distant sites likely affected by different SARS-CoV-2 variants (35) (since only 4 of the 48 centers were in Illinois or Colorado, most	9.4% reduction in primary event endpoint in CCP group, which rises to 20% after exclusion on patients admitted on the index visit	(23, 100)

									CCP usage had to be from remote sources); immunosuppressed individuals were nearly twice as common in the treatment group (12.8% vs 6.7%); designed to detect an absolute risk difference of 10% in disease progression (99)		
NCT04359810	223 (2:1)	FFP	9 from symptoms	5-7	1 200-250 ml unit	1:160	n.a.	at 28 days, no significant improvement in clinical status	very late usage; beneficial factors in FFP used in control arm (63)	lower mortality (12.6% vs. 24.6%) compared to nonconvalescent plasma	(11)
NCT04381858	190 (2:1)	IVIg	12 from symptoms	6 7 (85%)	2 200-ml units 24 hours apart	n.a. (29.5% received at least 1 unit of CCP with antibodies)	n.a.	no difference in mortality at day 28	very late usage; beneficial factors of IVIg used in control arm	none	(101)
NCT04344535	74 (out of 500) (4:1)	FFP	9 from symptoms, 4 from hospitalization	n.a.	2 200-ml units	1:526	n.a.	no difference in ventilator-free days or mortality (27% vs. 33% (at day 28	very late usage; beneficial factors in FFP used in control arm (63)	all-cause mortality through 90 days was numerically lower in the CCP versus standard plasma groups (27% vs 33%; p = 0.63)	(89)
NCT04433910 (CAPSID)	105 (1:1)	BSC	7 from symptoms	4-7	3 units from same donor over 5 days	1:160 ($PRNT_{50}$)	1:160 ($PRNT_{50}$)	not significant difference in the primary outcome (dichotomous composite outcome of survival and no	moderately late usage	median time to clinical improvement was 26 days in the CCP group and 66 days in the control group (p=0.27). Median time to discharge from hospital was	(34)

					(850 ml)			longer fulfilling criteria for severe COVID-19) and secondary outcomes		31 days (IQR 16-n.r.) in the CCP and 51 days (IQR 20-n.r.) in the control group (p=0.24). In the subgroup that received a higher cumulative amount of nAbs the primary outcome occurred in 56.0% (versus 32.1%), with a shorter interval to clinical improvement, shorter time to hospital discharge and better survival compared to the control group	
NCT04547660 (PLACOVID)	160 (1:1)	BSC	10 from symptom	37% 5-6 66% 7	2 300-ml aliquots 2 days apart,	n.a.	>1:80 in 83%	no difference in 28-day mortality, days alive, days free of respiratory support, duration of invasive ventilatory support, inflammatory and other laboratorial markers values on days 3, 7 and 14	very late usage	none	(102)
NCT04429854 (DAWN-plasma)	320 (2:1)	BSC	7 from symptoms		2 200-250 ml aliquots within 12 hours followed by 2	n.a.	≥1:320	no significant improvement proportion of patients that require mechanical ventilation or have died at day 15 or 30	late usage	none	(103, 104)

					units within 36 hours						
NCT04393727 (TSUNAMI)	417 (1:1)	BSC	> 7 from radiological diagnosis	4-5	2 200-ml aliquots	n.a.	1:226 (each unit > 1:160)	no statistically significant improvement in progression to ventilatory support or death	powered to detect an exaggerated 40% reduction in primary endpoint; underpowered for subgroup analysis; late usage; unexplained findings at site 02 (which recruited 40% of patients)	trends favoring CCP in basally seronegatives, P/F > 300 mmHg (p = 0.059), and recipients of units with higher nAb titres	(105)
NCT04600440 (COP20)	31 (out of 100) (1:1)	BSC	< 4 from positive NPS	5	3 200-250 ml aliquots	1:116 (each unit > 1:40)	n.a.	no significant difference in number of days of oxygen treatment to keep SaO2 > 93% or mortality at 28 days. Closed for futility	Focusing on patients with worse clinical course (oxygen requiring at day 4 since NPS); argely underpowered; more days passed since onset of symtoms to transfusion	none	(90)

* 0: no clinical or virological evidence of infection; 1 : no limitations of activities; 2 : limitations of activities ; 3 : hospitalized, no oxygen therapy; 4 : oxygen by mask or nasal prongs ; 5 : non-invasive ventilation or high-flow oxygen; 6 : intubation and mechanical ventilation ; 7 : ventilation + additional organ support - pressors, RRT, ECMO; 8 : death.

Table 3

Propensity score-matched (PSM) CCP studies reported to date. DPH: days post-hospitalization. None of these studies titered nAbs in either donor or recipient using NT.

time	country	patients+ controls	median days post-hospitalization	baseline recipient WHO score (21)	transfused CCP volume (ml)	statistically significant outcomes	Reason(s) for failure	ref
retrospective	Mount Sinai, NY, USA	39 + 156	4	5 (87%) 6 (10%)	250+250	on day 14 oxygen requirements worsened in 17.9% of plasma recipients versus 28.2% of controls (aOR 0.86). Survival improved in plasma recipients (aHR 0.34)	No failure	(42)
	Providence, RI, USA	64 + 177	> 2 (< 10 from onset of symptoms: median 7)	4 (70%) 5 (30%)	n.a. (2 units)	no significant differences in incidence of in-hospital mortality (12.5% and 15.8%; aHR 0.93) or overall rate of hospital discharge (RR 1.28, although increased among patients > 65-years)	Late usage	(45)
	Montefiore Medical Center, NY, USA	90 + 258	< 3 (3-7 days from onset of symptoms)	5-6 (< 24 hrs mechanical ventilation)	200	anti-S IgG titer ≥1:2,430 (median 1:47,385) recipients <65 years had 4-fold lower mortality and 4-fold lower deterioration in oxygenation or mortality at day 28	No failure	(41)
	Washington, USA	263+263	< 14	n.a.	245 (median)	reduced 7-day (9.1 vs. 19.8%) and 14-day mortality (14.8 vs. 23.6%), but not 28-day mortality (P = 0.06), and longer hospital stay	Late usage; control cohort was treated, on average, 29 days prior to the CCP cohort	(47)
	USA (176 HCA Healthcare-affiliated community hospitals)	3774 + 10687	< 3 vs. 4-7	n.a.	n.a.	lower mortality (aHR = 0.71) and faster recovery. CCP within 3 days after admission, but not 4-7 days, was associated with a significant reduction in mortality risk (aHR = 0.53). CCP serology level was inversely associated with mortality when controlling for interaction with days to transfusion (HR = 0.998) but was not significant in a univariable analysis	No failure	(48)
	China	163 + 163	23	n.a.	300	hospital stay in CCP group was significantly longer than matched control group (*P* < 0.0001).	Very late usage; more advanced disease in the CCP group (23 days vs.	(106)

							15 since hospital admission	
	Greece	59 + 59	7	≥ 4	200-233 ml (days 1, 3, and 5)	significantly reduced risk of death [HR: 0.04, 3.4% vs. 13.6%], significantly better overall survival by Kaplan-Meir analysis, and increased probability of extubation [OR: 30.3]. Higher levels of antibodies (as measured with Euroimmun or pseudoVNT) in CCP were independently associated with significantly reduced risk of death.	No failure	(107)
	New Haven, USA	132 + 2551	< 6 vs > 6 days	moderate to severe		early CCP recipients, of whom 31 (40%) were on mechanical ventilation, had lower 14-day (15% vs 23%) and 30-day (38% vs 49%) mortality compared to a matched unexposed cohort, with nearly 50% lower likelihood of in-hospital mortality (HR 0.52). Early plasma recipients had more days alive and ventilator-free at 30 days (+3.3 days) and improved WHO scores at 7 days (-0.8) and hospital discharge (-0.9) compared to the matched unexposed cohort	No failure	(46)
	USA	143+823 (hematogic al cancer)	n.a.	n.a.	n.a.	improved 30-day mortality (HR, 0.52; 95% CI, 0.29-0.92). Among the 338 patients admitted to the ICU, mortality was significantly lower in CCP recipients compared with nonrecipients (HR 0.40). Among the 227 patients who required mechanical ventilatory support, mortality was significantly lower in CCP recipients compared with nonrecipients (HR 0.32).	No failure	(76)
prospective	Houston, USA	136 + 251	n.a.	3 (9%) 4 (63%) 5 (18%) 6 (10%) 7 (1%)	300 (1-2 units)	reduction in mortality within 28 days, specifically in patients transfused < 72 hours of admission with CCP with an anti-RBD titer ≥1:1350 (i.e., ~80% probability of a live virus *in vitro* neutralization titer of ≥1:160 (108))	No failure	(43)
		341 + 594	n.a.		300 (1-2 units)	reduced 28-day (aHR=2.09 for controls) and 60-day (5.7% vs. 10.7%; aHR=1.82 for controls) mortality in those transfused with anti-RBD ≥1:1350 within 72 hours	No failure	(44)

						post-hospitalization. Optimal window of 44 hours to maximize benefit in 60 days mortality (4% vs 12.3%). 91% received CCP with an anti-RBD titer ≥1:1350. median S/CO ratio =24 using Ortho Vitros.		
	Poland	102 + 102	n.a.	n.a.	n.a.	lower mortality rate (13.7% vs. 34.3%; OR=0.25) related to time of first administration (12.2% at day 5, 21.5% at day 10), no significant differences in ICU stay, ventilator time, and hospitalization time. Earlier administration resulted in a ventilator being needed for a shorter length of time (*r* = 0.41)	No falure	(109)
	Colorado (16 hospitals)	188 + 188	n.a.	n.a.	1 unit if < 90 kg; 2 units if > 90kg	increased length of hospital stay in CCP-treated patients and no change in inpatient mortality compared to controls. In subgroup analysis of CCP-treated patients within 3 or 7 days of admission, there was no difference in length of hospitalization and inpatient mortality.	Covariate matching not achieved for subgroup receiving CCP < 3 days	(110)

Table 4

Summary of completed but not yet reported or ongoing RCTs of CCP, as registered on ClinicalTrials.gov as of August 26, 2021. BSC: best supportive care; FFP: fresh frozen plasma. Several studies were withdrawn (NCT04377568).

Status	NCT number	Patient subtype	Control arm	Study design	Number planned to enrol	Study start	Locations
Completed	NCT04332835	severe (SOFA <6)	BSC	single masking (outcomes assessor)	92	August 8, 2020	Colombia
	NCT04349410	any	10 different arms	single masking (investigator)	1800	April 11, 2020	USA
	NCT04397757	ordinal scale 5 to 7	BSC	open label	80	May 30, 2020	USA
	NCT04421404	within 3 days from hospitalization or 14 from symptoms	placebo	triple masking (participant, care provider, investigator)	34		USA
	NCT04374526	pneumonia, age > 65 and PaO2/FiO2 ≥300 mmHg and comorbidities	BSC	open label	29	May 27, 2020	Italy
	NCT04358783	hospitalized requiring supplemental oxygen	BSC	quadruple masking (participant, care provider, investigator, outcomes assessor)	30	April 27, 2020	Mexico
	NCT04405310	moderate to severe requiring supplemental oxygen	albumin	double (participant, care provider)	80	May 20, 2020	Mexico
	NCT04425915	on ventilator within 3 days from onset of symptoms	BSC	open label	400	June 14, 2020	India
Active, not recruiting	NCT04539275	ventilated and within 3 days from hospitalization	masked saline placebo	triple masking (participant, care provider, investigator)	702	November 16, 2020	USA
	NCT04374487	hospitalized and severe	BSC	open label	100	May 9, 2020	India
	NCT04323800	exposed within 96 h	FFP	triple masking (participant, care provider, investigator)	500	June 10, 2020	USA

		of enrollment and 120 h of receipt of CCP					
	NCT04364737 (CONTAIN)	hospitalized and within 7 days from symptoms	placebo	double masking (participant, investigator)	300	April 17, 2020	USA
	NCT04425837	high-risk	BSC	single masking (outcomes assessor)	236	July 2020	Colombia
	NCT04395170	hospitalized	2 arms (BSC; anti-COVID-19 IVIG)	open label	75	September 2020	Colombia
	NCT04391101	severe	BSC	open label	231	June 2020	Colombia
Recruiting	NCT04516811	moderate to severe	placebo	triple masking (participant, care provider, investigator)	600	September 21, 2020	South Africa
	NCT04388410	hospitalized, severe disease or risk for severe diseases	BSC	quadruple masking (participant, care provider, investigator, outcomes assessor)	410	August 25, 2020	Mexico
	NCT04385043	severe Infection	BSC	open label	400	May 1, 2020	Italy
	NCT04380935	acute respiratory distress syndrome	BSC	open label	60	May 18, 2020	Indonesia
	NCT04362176 (PassItOn)	hospitalized adults	placebo	triple masking (participant, care provider, outcomes assessor)	1000	April 24, 2020	USA
	NCT04390503	exposed within 7 days or mild symptoms within 5 days	albumin	double masking (participant, outcome assessor)	150	March 12, 2021	USA
	NCT04376034	severe or life-threatening	BSC	open label	240	March 30, 2021	USA
	NCT04373460	outpatients within 8 days from symptoms	FFP	triple masking (participant, care provider, outcomes assessor)	1344	June 3, 2020	USA
	NCT04366245	hospitalized ventilated	BSC	open label	72	April 23, 2020	Spain
	NCT04333251	hospitalized within 7 days from symptoms	BSC	open label	115	April 1, 2020	USA
	NCT04345991	mild and within 8	BSC	open label	120	April 15, 2020	France

		days from symptoms					
	NCT04372979	hospitalized within 10 days from symptoms	FFP	triple masking (participant, care provider, outcomes assessor)	80	September 14, 2020	France
	NCT04345289	adults with pneumonia	placebo	quadruple masking (participant, care provider, investigator, outcomes assessor)	1100	May 1, 2020	Denmark

References

1. Casadevall A, Pirofski LA, Joyner MJ. 2021. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. mBio 12:e03372-20.
2. Casadevall A, Pirofski L-a. 2020. The convalescent sera option for containing COVID-19. The Journal of Clinical Investigation 130.
3. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. 2010. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38:e66-73.
4. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. 2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences doi:10.1073/pnas.2004168117:202004168.
5. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. 2020. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 324:460-470.
6. Perotti C, Baldanti F, Bruno R, Delfante C, Seminari E, Casari S, Percivalle E, Glingani C, Musella V, Belliato M, Garuti M, Meloni F, Frigato M, Di Sabatino A, Klersy C, De Donno G, Franchini M. 2020. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. Haematologica 105:2834-2840.
7. Focosi D, Anderson AO, Tang JW, Tuccori M. 2020. Convalescent Plasma Therapy for COVID-19: State of the Art. Clin Microbiol Rev 33:e00072-20.
8. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas AM, Wiggins CC, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW, Lesser ER, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Hodge DO, Kunze KL, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van Buskirk CM, Winters JL, Stubbs JR, Paneth NS, Verdun NC, Marks P, Casadevall A. 2020. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest doi:10.1172/jci140200.
9. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA, Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd JRA, van Helmond N, Verdun NC, Marks P, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, Hodge DO, Herasevich V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Paneth NS, Fairweather D, Wright RS, Casadevall A. 2021. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med 384:1015-1027.
10. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, Latha B, Bundas S, Kumar V, Dosi R, Khambholja JK, de Souza R, Mesipogu RR, Srivastava S, Dube S, Chaudhary K, S S, Mattuvar K SA, Rajendran V, Sundararajaperumal A, Balamanikandan P, Maheswari RSU, Jayanthi R, Ragunanthanan S, Bhandari S, Singh A, Pal A, Handa A, Rankawat G, Kargirwar K, Regi J, Rathod D, Pathrose E, Bhutaka N, Patel MH, Verma RJ, Malukani K, Patel S, Thakur A, Joshi S, Kulkarni R, Suthar NN, Shah NM, Purohit HM, Shah CK, Patel MN, Shah S, Shah SH, Memon T, Beriwala VR, et al. 2020. Convalescent plasma in the management of moderate COVID-19 in India: open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). BMJ 371:m3939.
11. O'Donnell MR, Grinsztejn B, Cummings MJ, Justman J, Lamb MR, Eckhardt CM, Philip NM, Cheung YK, Gupta V, João E, Pilotto JH, Diniz MP, Cardoso SW, Abrams D, Rajagopalan K, Borden S, Wolf A, Sidi LC, Vizzoni A, Veloso VG, Bitan ZC, Scotto DE, Meyer BJ, Jacobson SD, Kantor A, Mishra N, Chauhan LV, Stone E, Dei Zotti F, La Carpia F, Hudson KE, Ferrera SA,

590 Schwartz J, Stotler B, Lin W-H, Wontakal S, Shaz B, Briese T, Hod EA, Spitalnik SL, Eisenberger
591 A, Lipkin WI. 2021. A randomized, double-blind, controlled trial of convalescent plasma in
592 adults with severe COVID-19. J Clin Invest doi:10.1172/JCI150646:150646.
593 12. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N,
594 Giunta DH, Pérez LG, Sánchez MdL, Gamarnik AV, Ojeda DS, Santoro DM, Camino PJ, Antelo
595 S, Rainero K, Vidiella GP, Miyazaki EA, Cornistein W, Trabadelo OA, Ross FM, Spotti M,
596 Funtowicz G, Scordo WE, Losso MH, Ferniot I, Pardo PE, Rodriguez E, Rucci P, Pasquali J,
597 Fuentes NA, Esperatti M, Speroni GA, Nannini EC, Matteaccio A, Michelangelo HG, Follmann
598 D, Lane HC, Belloso WH. 2020. A Randomized Trial of Convalescent Plasma in Covid-19
599 Severe Pneumonia. N Engl J Med 384:619-629.
600 13. Pirofski LA, Casadevall A. 2020. Pathogenesis of COVID-19 from the Perspective of the
601 Damage-Response Framework. mBio 11.
602 14. Van Rompay KKA, Olstad KJ, Sammak RL, Dutra J, Watanabe JK, Usachenko JL, Immareddy R,
603 Roh JW, Verma A, Lakshmanappa YS, Schmidt BA, Germanio CD, Rizvi N, Stone M, Simmons
604 G, Dumont LJ, Allen AM, Lockwood S, Pollard RE, de Assis RR, Yee JL, Nham PB, Ardeshir A,
605 Deere JD, Patterson J, Jain A, Felgner PL, Iyer SS, Hartigan-O'Connor DJ, Busch MP, Reader
606 JR. 2021. Early post-infection treatment of SARS-CoV-2 infected macaques with human
607 convalescent plasma with high neutralizing activity reduces lung inflammation.
608 doi:10.1101/2021.09.01.458520 %J bioRxiv:2021.09.01.458520.
609 15. Focosi D, Maggi F, Franchini M, Aguzzi A, Lanza M, Mazzoni A, Menichetti F. 2021. Patient-
610 blood management for COVID19 convalescent plasma therapy: relevance of affinity and
611 donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect
612 doi:10.1016/j.cmi.2021.04.003.
613 16. Alamgir J, Abid R, Garibaldi BT, Munir N, Setoguchi S, Hong SS, Chen X, Kocis PT, Yajima M,
614 Alexander GC, Mehta HB, Madhira V, Ergas R, O'Brien TR, Bozzette S. 2021. Lack of
615 association between convalescent plasma administration and length of hospital stay: a
616 hospital-day stratified multi-center retrospective cohort study. medrXiv [Preprint]
617 doi:10.1101/2021.05.04.21256627 %J medRxiv:2021.05.04.21256627.
618 17. Kocayiğit H, Demir G, Karacan A, Süner K, Tomak Y, Yaylacı S, Dheir H, Kalpakci Y, Erdem AF.
619 2021. Effects on mortality of early vs late administration of convalescent plasma in the
620 treatment of Covid-19. Transfus Apher Sci doi:10.1016/j.transci.2021.103148:103148.
621 18. Focosi D, Navarro D, Maggi F, Roilides E, Antonelli G. 2021. COVID-19 infodemics: the role of
622 mainstream and social media. Clin Microbiol Infect doi:10.1016/j.cmi.2021.08.003.
623 19. Harrell F, Lindsell C. 2021. Statistical Design and Analysis Plan for Sequential Parallel-Group
624 RCT for COVID-19.
625 20. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M,
626 Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F,
627 Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de
628 la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J. 2021. Immunogenicity
629 and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a
630 multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 398:121-130.
631 21. WHO. 2020. R & D Blueprint - novel Coronavirus COVID19 Therapeutic Trial Synopsis.
632 https://www.who.int/blueprint/priority-diseases/key-action/COVID-
633 19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf?ua=1.
634 Accessed October 1.
635 22. Anonymous. 2020. A minimal common outcome measure set for COVID-19 clinical research.
636 Lancet Infect Dis 20:e192-e197.
637 23. Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, El Kassar
638 N, Foster LD, Hah JM, Jaiswal S, Kaplan A, Lowell E, McDyer JF, Quinn J, Triulzi DJ, Van
639 Huysen C, Stevenson VLW, Yadav K, Jones CW, Kea B, Burnett A, Reynolds JC, Greineder CF,

640 Haas NL, Beiser DG, Silbergleit R, Barsan W, Callaway CW. 2021. Early Convalescent Plasma
641 for High-Risk Outpatients with Covid-19. N Engl J Med doi:10.1056/NEJMoa2103784.
642 24. Epstein J, Burnouf T. 2020. Points to consider in the preparation and transfusion of COVID-19
643 convalescent plasma. Vox Sang 115:485-487.
644 25. Focosi D, Mazzetti P, Pistello MM, F. 2020. Viral infection neutralization tests: a focus on
645 SARS-CoV-2 with implications for convalescent plasma therapy. Rev Med Virol
646 doi:10.1002/rmv.2170:e2170.
647 26. Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, Romano M,
648 Barbezange C, Maes P, Van Holm B, Mendoza J, Oyonarte S, Fomsgaard A, Lassaunière R,
649 Zusinaite E, Resman Rus K, Avšič-Županc T, Reimerink JH, Brouwer F, Hoogerwerf M,
650 Reusken CB, Grodeland G, Le Cam S, Gallian P, Amroun A, Brisbarre N, Martinaud C, Leparc
651 Goffart I, Schrezenmeier H, Feys HB, van der Schoot CE, Harvala H. 2021. SARS-CoV-2
652 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody
653 titres for better use of convalescent plasma and comparability of trial data. Euro Surveill 26.
654 27. Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung C-T, Enyindah-
655 Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoever J, Jurczyszak D,
656 Bermudez-Gonzalez M, Simon V, Nádas A, Liu S, Lee B, Krammer F, Zolla-Pazner S, Hioe CE.
657 2020. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. medrXiv
658 [Preprint] doi:10.1101/2020.08.18.20177303 %J medRxiv:2020.08.18.20177303.
659 28. Egloff SAA, Junglen A, Restivo JSA, Wongskhaluang M, Martin C, Doshi P, Schlauch D, Fromell
660 G, Sears LE, Correll M, Burris HA, LeMaistre CF. 2021. Convalescent plasma associates with
661 reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J
662 Clin Invest doi:10.1172/JCI151788.
663 29. Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, Littlefield K, Wieland-Alter
664 W, Connor RI, Wright PF, Benner SE, Bonny TS, Laeyendecker O, Sullivan D, Shoham S, Quinn
665 TC, Larman HB, Casadevall A, Pekosz A, Redd AD, Tobian AAR, Ackerman ME. 2021. Markers
666 of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. mBio 12.
667 30. Horby PW, Estcourt L, Peto L, Emberson JR, Staplin N, Spata E, Pessoa-Amorim G, Campbell
668 M, Roddick A, Brunskill NE, George T, Zehnder D, Tiberi S, Aung NN, Uriel A, Widdrington J,
669 Koshy G, Brown T, Scott S, Baillie JK, Buch MH, Chappell LC, Day JN, Faust SN, Jaki T, Jeffery
670 K, Juszczak E, Lim WS, Montgomery A, Mumford A, Rowan K, Thwaites G, Mafham M,
671 Roberts D, Haynes R, Landray MJ. 2021. Convalescent plasma in patients admitted to
672 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
673 Lancet 397:2049-2059.
674 31. Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN,
675 Stalenhoef JE, Dofferhoff A, Ludwig I, Koster A, Hassing R-J, Bos JC, van Pottelberge GR,
676 Vlasveld IN, Ammerlaan HSM, Segarceanu E, Miedema J, van der Eerden M, Papageorgiou G,
677 te Broekhorst P, Swaneveld FH, Katsikis PD, Mueller Y, Okba NMA, Koopmans MPG,
678 Haagmans BL, Rokx C, Rijnders B. 2021. Effects of potent neutralizing antibodies from
679 convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Comm
680 12:3189.
681 32. Del Fante C, Franchini M, Baldanti F, Percivalle E, Glingani C, Marano G, Mengoli C,
682 Mortellaro C, Viarengo G, Perotti C, Liumbruno GM. 2020. A retrospective study assessing
683 the characteristics of COVID-19 convalescent plasma donors and donations. Transfusion
684 61:830-838.
685 33. Mehew J, Johnson R, Roberts D, Harvala H. 2020. Convalescent plasma for COVID-19: male
686 gender, older age and hospitalisation associated with high neutralising antibody levels,
687 England, 22 April to 12 May 2020. Euro Surveill 25:2001754.
688 34. Koerper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, Gruener B, Ernst L,
689 Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhenn J, Dollinger M, Rosenberger P,
690 Kirschning T, Thiele T, Appl T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Jungwirth B,

691 Seifried E, Schrezenmeier H. 2021. Results of the CAPSID randomized trial for high-dose
692 convalescent plasma in severe COVID-19 patients. J Clin Invest
693 doi:10.1172/JCI152264:2021.05.10.21256192.
694 35. Kunze KL, Johnson PW, van Helmond N, Senefeld JW, Petersen MM, Klassen SA, Wiggins CC,
695 Klompas AM, Bruno KA, Mills JR, Theel ES, Buras MR, Golafshar MA, Sexton MA, Diaz Soto JC,
696 Baker SE, Shepherd JRA, Verdun NC, Marks P, Paneth NS, Fairweather D, Wright RS, van
697 Buskirk CM, Winters JL, Stubbs JR, Senese KA, Pletsch MC, Buchholtz ZA, Rea RF, Herasevich
698 V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Lesser ER, Vogt MNP, Dennis JJ,
699 Regimbal RJ, Bauer PR, Blair JE, Casadevall A, Carter RE, Joyner MJ. 2021. Mortality in
700 individuals treated with COVID-19 convalescent plasma varies with the geographic
701 provenance of donors. Nat Commun 12:4864.
702 36. Rochman ND, Wolf YI, Faure G, Mutz P, Zhang F, Koonin EV. 2021. Ongoing global and
703 regional adaptive evolution of SARS-CoV-2. Proc Natl Acad Sci U S A 118.
704 37. Junker D, Dulovic A, Becker M, Wagner TR, Kaiser PD, Traenkle B, Rothbauer U, Kienzle K,
705 Bunk S, Strümper C, Häberle H, Schmauder K, Malek N, Althaus K, Koeppen M, Bitzer M,
706 Göpel S, Schneiderhan-Marra N. 2021. Reduced serum neutralization capacity against SARS-
707 CoV-2 variants in a multiplex ACE2 RBD competition assay.
708 doi:10.1101/2021.08.20.21262328 %J medRxiv:2021.08.20.21262328.
709 38. Chalmers TC, Matta RJ, Smith H, Jr., Kunzler AM. 1977. Evidence favoring the use of
710 anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 297:1091-
711 6.
712 39. Senefeld JW, Johnson PW, Kunze KL, van Helmond N, Klassen SA, Wiggins CC, Bruno KA,
713 Golafshar MA, Petersen MM, Buras MR, Klompas AM, Sexton MA, Diaz Soto JC, Baker SE,
714 Shepherd JRA, Verdun NC, Marks P, van Buskirk CM, Winters JL, Stubbs JR, Rea RF,
715 Herasevich V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis
716 JJ, Regimbal RJ, Bauer PR, Blair JE, Wright K, Greenshields JT, Paneth NS, Fairweather D,
717 Wright RS, Casadevall A, Carter RE, Joyner MJ. 2021. Program and patient characteristics for
718 the United States Expanded Access Program to COVID-19 convalescent plasma. medrXiv
719 [Preprint] doi:10.1101/2021.04.08.21255115 %J medRxiv:2021.04.08.21255115.
720 40. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA,
721 Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd JRA, van
722 Helmond N, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, Hodge DO, Herasevich V, Whelan
723 ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Dennis JJ, Regimbal
724 RJ, Bauer PR, Blair JE, Paneth NS, Fairweather D, Wright RS, Carter RE, Casadevall A. 2020.
725 Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19:
726 Initial Three-Month Experience. medRxiv doi:10.1101/2020.08.12.20169359 %J
727 medRxiv:2020.08.12.20169359.
728 41. Yoon Ha, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz RH, Wirchnianski AS, Paroder M,
729 Fehn K, Serrano-Rahman L, Babb R, Sarwar UN, Haslwanter D, Laudermilch E, Florez C,
730 Dieterle ME, Jangra RK, Fels JM, Tong K, Mariano MC, Vergnolle O, Georgiev GI, Herrera NG,
731 Malonis RJ, Quiroz JA, Morano NC, Krause GJ, Sweeney JM, Cowman K, Allen S, Annam J,
732 Applebaum A, Barboto D, Khokhar A, Lally BJ, Lee A, Lee M, Malaviya A, Sample R, Yang XA,
733 Li Y, Ruiz R, Thota R, Barnhill J, Goldstein DY, Uehlinger J, Garforth SJ, Almo SC, Lai JR, Gil MR,
734 et al. 2021. Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC. JCI
735 Insight doi:10.1172/jci.insight.142270:142270.
736 42. Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P,
737 Bassily-Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Nguyen FT, Amanat F, Stadlbauer D,
738 Altman DR, Chen BK, Krammer F, Mendu DR, Firpo-Betancourt A, Levin MA, Bagiella E,
739 Casadevall A, Cordon-Cardo C, Jhang JS, Arinsburg SA, Reich DL, Aberg JA, Bouvier NM. 2020.
740 Convalescent plasma treatment of severe COVID-19: a propensity score–matched control
741 study. Nature Medicine 26:1708-1713.

742 43. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X,
743 Zhao P, Rogers J, Shehabeldin A, Joseph D, Leveque C, Olsen RJ, Bernard DW, Gollihar J,
744 Musser JM. 2020. Treatment of Coronavirus Disease 2019 Patients with Convalescent
745 Plasma Reveals a Signal of Significantly Decreased Mortality. Am J Pathol 190:2290-2303.
746 44. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X,
747 Zhao P, Rogers J, Shehabeldin A, Joseph D, Masud F, Leveque C, Olsen RJ, Bernard DW,
748 Gollihar J, Musser JM. 2021. Significantly Decreased Mortality in a Large Cohort of
749 Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma
750 Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
751 Spike Protein IgG. Am J Pathol 191:90-107.
752 45. Rogers R, Shehadeh F, Mylona EK, Rich J, Neill M, Touzard-Romo F, Geffert S, Larkin J, Bailey
753 JA, Lu S, Sweeney J, Mylonakis E. 2020. Convalescent plasma for patients with severe COVID-
754 19: a matched cohort study. Clin Infect Dis ciaa1548:Epub ahead of print.
755 46. Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng
756 Y, Hendrickson JE, Tormey CA, Desruisseaux MS. 2021. Early but not late convalescent
757 plasma is associated with better survival in moderate-to-severe COVID-19. PLoS One
758 16:e0254453.
759 47. Shenoy AG, Hettinger AZ, Fernandez SJ, Blumenthal J, Baez V. 2021. Early mortality benefit
760 with COVID-19 convalescent plasma: a matched control study. Br J Haematol
761 doi:10.1111/bjh.17272.
762 48. Arnold Egloff SA, Junglen A, Restivo JSA, Wongskhauluang M, Martin C, Doshi P, Schlauch D,
763 Fromell G, Sears LE, Correll M, Burris HA, LeMaistre CF. 2021. Association of Convalescent
764 Plasma Treatment with Reduced Mortality and Improved Clinical Trajectory in Patients
765 Hospitalized with COVID-19 in the Community Setting. doi:10.1101/2021.06.02.21258190
766 %J medRxiv:2021.06.02.21258190.
767 49. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT,
768 Wood C, Berrueta M, Rondan A, Lescano G, Cruz P, Ritou Y, Fernández Viña V, Álvarez Paggi
769 D, Esperante S, Ferreti A, Ofman G, Ciganda Á, Rodriguez R, Lantos J, Valentini R, Itcovici N,
770 Hintze A, Oyarvide ML, Etchegaray C, Neira A, Name I, Alfonso J, López Castelo R, Caruso G,
771 Rapelius S, Alvez F, Etchenique F, Dimase F, Alvarez D, Aranda SS, Sánchez Yanotti C, De Luca
772 J, Jares Baglivo S, Laudanno S, Nowogrodzki F, Larrea R, Silveyra M, Leberzstein G, Debonis A,
773 Molinos J, González M, Perez E, et al. 2021. Early High-Titer Plasma Therapy to Prevent
774 Severe Covid-19 in Older Adults. N Engl J Med 384:610-618.
775 50. Ray Y, Paul SR, Bandopadhyay P, D'Rozario R, Sarif J, Lahiri A, Bhowmik D, Vasudevan JS,
776 Maurya R, Kanakan A, Sharma S, Kumar M, Singh P, Roy R, Chaudhury K, Maiti R, Bagchi S,
777 Maiti A, Perwez MM, Mondal A, Tewari A, Mandal S, Roy A, Saha M, Biswas D, Maiti C,
778 Chakraborty S, Sarkar BS, Haldar A, Saha B, Sengupta S, Pandey R, Chatterjee S, Bhattacharya
779 P, Paul S, Ganguly D. 2020. Clinical and immunological benefits of convalescent plasma
780 therapy in severe COVID-19: insights from a single center open label randomised control
781 trial. medRxiv doi:10.1101/2020.11.25.20237883 %J medRxiv:2020.11.25.20237883.
782 51. Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, Malo de Molina R,
783 Torres F, Fernandez-Cruz A, Callejas-Diaz A, Calderon J, Payares-Herrera C, Salcedo I, Romera
784 I, Lora-Tamayo J, Mancheno-Losa M, Paciello ML, Villegas C, Estrada V, Saez-Serrano I,
785 Porras-Leal ML, Jarilla-Fernandez MdC, Pano-Pardo JR, Moreno-Chulilla JA, Arrieta-Aldea I,
786 Bosch A, Belhassen-Garcia M, Lopez-Villar O, Ramos-Garrido A, Blanco L, Madrigal ME,
787 Contreras E, Muniz-Diaz E, Domingo-Morera JM, Casas-Flecha I, Perez-Olmeda M, Garcia-
788 Perez J, Alcami J, Bueno JL, Duarte RF. 2021. A multicenter randomized open-label clinical
789 trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest
790 doi:10.1172/JCI152740:152740.
791 52. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, Smith ER, Haber NA,
792 Khanna N, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. 2021. Association of

793 Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A
794 Systematic Review and Meta-analysis. JAMA 325:1185-1195.
795 53. Hamilton FW, Lee TC, Arnold DT, Lilford RJ, Hemming K. 2021. Is convalescent plasma futile
796 in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial. Int J
797 Infect Dis S1201-9712:00523-3.
798 54. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, Grossman BJ,
799 Henderson JP, Musser J, Salazar E, Hartman WR, Bouvier NM, Liu STH, Pirofski LA, Baker SE,
800 van Helmond N, Wright RS, Fairweather D, Bruno KA, Wang Z, Paneth NS, Casadevall A,
801 Joyner MJ. 2021. The Effect of Convalescent Plasma Therapy on Mortality Among Patients
802 With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc 96:1262-1275.
803 55. Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, Monsef I, Wood EM, Lamikanra
804 AA, Roberts DJ, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. 2021. Convalescent plasma
805 or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
806 Cochrane Database Syst Rev 5:Cd013600.
807 56. Cruciani M, Bongiovanni G, Franchini M. 2021. High-titer convalescent plasma therapy for
808 coronavirus disease 2019 and mortality. Transfusion 61:1988-1990.
809 57. Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, van Helmond N,
810 Bruno KA, Pirofski LA, Shoham S, Grossman BJ, Henderson JP, Wright RS, Fairweather D,
811 Paneth NS, Carter RE, Casadevall A, Joyner MJ. 2021. Convalescent Plasma Therapy for
812 COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne) 8:684151.
813 58. Casadevall A, Grossman BJ, Henderson JP, Joyner MJ, Paneth NS, Pirofski LA, Shoham S.
814 2021. Please Reevaluate the Data on Convalescent Plasma for COVID-19.
815 https://www.medpagetoday.com/opinion/second-opinions/94256?xid=nl_mpt_DHE_2021-
816 08-
817 30&eun=g1783322d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%
818 20Headlines%20Top%20Cat%20HeC%20%202021-08-30&utm_term=NL_Daily_DHE_dual-
819 gmail-definition. Accessed August 31, 2021.
820 59. de Candia P, Prattichizzo F, Garavelli S, La Grotta R, De Rosa A, Pontarelli A, Parrella R,
821 Ceriello A, Matarese G. 2021. Effect of time and titer in convalescent plasma therapy for
822 COVID-19. iScience doi:10.1016/j.isci.2021.102898:102898.
823 60. Kloypan C, Saesong M, Sangsuemoon J, Chantharit P, Mongkhon P. 2021. Convalescent
824 Plasma for COVID-19: A Meta-analysis of Clinical Trials and Real-World Evidence. Eur J Clin
825 Invest doi:10.1111/eci.13663:e13663.
826 61. Franchini M, Focosi D, Corsini F, Cruciani M. 2021. Safety and efficacy of convalescent
827 plasma in COVID-19: an overview of systematic reviews. Diagnostics.
828 62. Anonymous. 2021. Continuous Monitoring of Pooled International Trials of Convalescent
829 Plasma for COVID-19 Hospitalized Patients. https://med.nyu.edu/departments-
830 institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-
831 monitoring-pooled-international-trials-convalescent-plasma-covid19-hospitalized-patients.
832 Accessed August 31, 2021.
833 63. Focosi D, Franchini M, Pirofski L-a, Burnouf T, Fairweather D, Joyner MJ, Casadevall A. 2021.
834 COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of
835 Potential Beneficial and Detrimental Co-Factors. Viruses 13:1594.
836 64. Franchini M, Cruciani M. 2021. How Safe Is COVID-19 Convalescent Plasma? Mayo Clin Proc
837 96:2279-2281.
838 65. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, Wiggins CC, Senefeld JW,
839 Klompas AM, Hodge DO, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Baker
840 SE, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal
841 RJ, Bauer PR, Blair JE, van buskirk CM, Winters JL, Stubbs JR, van Helmond N, Butterfield BP,
842 Sexton M, Diaz Soto J, Paneth NS, Verdun NC, Marks P, Casadevall A, Fairweather D, Carter

843 RE, Wright RS. 2020. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized
844 Patients. Mayo Clinic Proceedings 95:1888-95.
845 66. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. 2020. Antibody-dependent enhancement and
846 SARS-CoV-2 vaccines and therapies. Nature Microbiology 5:1185-1191.
847 67. Focosi D, Franchini M. 2021. Potential use of convalescent plasma for SARS-CoV-2
848 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Rev
849 Vaccines doi:10.1080/14760584.2021.1932475:1-8.
850 68. Vickers MA, Sariol A, Leon J, Ehlers A, Locher AV, Dubay KA, Collins L, Voss D, Odle AE, Holida
851 M, Merrill AE, Perlman S, Knudson CM. 2021. Exponential increase in neutralizing and spike
852 specific antibodies following vaccination of COVID-19 convalescent plasma donors.
853 Transfusion doi:10.1111/trf.16401.
854 69. Anonymous. 2021. CoVIg-19 Plasma Alliance Announces Topline Results from NIH-
855 Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine.
856 https://www.takeda.com/newsroom/newsreleases/2021/covig-19-plasma-alliance-
857 announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-
858 hyperimmune-globulin-medicine/. Accessed April 2, 2021.
859 70. Anonymous. 2020. ACTIV-3/TICO LY-CoV555 Study Group. A Neutralizing Monoclonal
860 Antibody for Hospitalized Patients with Covid-19. N Engl J Med 384:905-914.
861 71. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J,
862 Heller B, Morris J, Crystal C, Igbinadolor A, Huhn G, Cardona J, Shawa I, Kumar P, Adams AC,
863 Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE,
864 Kallewaard NL, Sabo J, Patel DR, Dabora MC, Klekotka P, Shen L, Skovronsky DM. 2021.
865 Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. NEJM
866 doi:10.1056/NEJMoa2102685.
867 72. Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SS, Wright SR, Joyner MJ,
868 Paneth N, Carter R. 2021. Convalescent Plasma Use in the United States was inversely
869 correlated with COVID-19 Mortality: Did Convalescent Plasma Hesitancy cost lives? Elife
870 4:e69866.
871 73. Focosi D, Franchini M. 2021. COVID-19 convalescent plasma therapy: hit fast, hit hard! . Vox
872 Sang.
873 74. Focosi D, Franchini M. 2021. COVID-19 neutralizing antibody-based therapies in humoral
874 immune deficiencies: A narrative review. Transfus Apher Sci
875 doi:10.1016/j.transci.2021.103071:103071.
876 75. Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, Thompson MA, Baker
877 SE, Nicholson WT, Johnson PW, Carter RE, Henderson JP, Hartman WR, Pirofski LA, Wright
878 RS, Fairweather L, Bruno KA, Paneth NS, Casadevall A, Joyner MJ. 2021. Use of convalescent
879 plasma in COVID-19 patients with immunosuppression. Transfusion 61:2503-2511.
880 76. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB,
881 Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-
882 Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL. 2021. Association of
883 Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and
884 COVID-19. JAMA Oncol doi:10.1001/jamaoncol.2021.1799.
885 77. Casadevall A, Henderson J, Joyner M, Pirofski L-a. 2021. SARS-Cov2 variants and
886 convalescent plasma: reality, fallacies, and opportunities. The Journal of Clinical
887 Investigation doi:10.1172/JCI148832.
888 78. Moscato G, Mazzetti P, Lucenteforte E, Rosellini A, Cara A, Quaranta P, Mainardi V, Villa P,
889 Focosi D, Lanza M, Bianco I, Mazzoni A, Falcone M, Menichetti F, Maggi F, Lai M, Freer G,
890 Pistello M. 2021. Assessment of automated high-throughput serological assays for prediction
891 of high-titer SARS-CoV-2 neutralizing antibody. Journal of Clinical Virology Plus 1:100016.
892 79. Jahrsdörfer B, Kroschel J, Ludwig C, Corman VM, Schwarz T, Körper S, Rojewski M, Lotfi R,
893 Weinstock C, Drosten C, Seifried E, Stamminger T, Groß HJ, Schrezenmeier H. 2021.

894 Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-
895 CoV-2 Antibody Testing. J Infect Dis 223:796-801.
896 80. Di Germanio C, Simmons G, Kelly K, Martinelli R, Darst O, Azimpouran M, Stone M, Hazegh K,
897 Grebe E, Zhang S, Ma P, Orzechowski M, Gomez JE, Livny J, Hung DT, Vassallo R, Busch MP,
898 Dumont LJ. 2021. SARS-CoV-2 Antibody persistence in COVID-19 convalescent plasma
899 donors: Dependency on assay format and applicability to serosurveillance. Transfusion
900 doi:10.1111/trf.16555:2021.03.24.21254260.
901 81. Misset B, Hoste E, Donneau A-F, Grimaldi D, Meyfroidt G, Moutschen M, Compernolle V,
902 Gothot A, Desmecht D, Garigliany M, Najdovski T, Laterre P-F. 2020. A multicenter
903 randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with
904 Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the
905 CONFIDENT trial protocol. BMC Pulmonary Medicine 20:317.
906 82. Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, Widdowson MA,
907 Mortgat L, Duysburgh E, Desombere I, Jansens H, Van Esbroeck M, Ariën KK. 2021.
908 Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in
909 severe and mild COVID-19 cases using a Luminex bead-based assay. J Virol Methods
910 288:114025.
911 83. Betrains A, Godinas L, Woei AJF, Rosseels W, Van Herck Y, Lorent N, Dierickx D, Compernolle
912 V, Meyfroidt G, Vanderbeke L, Vergote V, Lagrou K, Verhamme P, Wauters J, Vermeersch P,
913 Devos T, Maes P, Vanderschueren S. 2021. Convalescent plasma treatment of persistent
914 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with
915 lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J
916 Haematol 192:1100-1105.
917 84. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM,
918 Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-
919 Fidouh N, Reusken C, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL. 2020. Severe
920 Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus
921 Disease Patients. Emerg Infect Dis 26:1478-1488.
922 85. Amanat F, White KM, Miorin L, Strohmeier S, McMahon M, Meade P, Liu W-C, Albrecht RA,
923 Simon V, Martinez-Sobrido L, Moran T, García-Sastre A, Krammer F. 2020. An In Vitro
924 Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. 58:e108.
925 86. Oguntuyo KY, Stevens CS, Hung C-T, Ikegame S, Acklin JA, Kowdle SS, Carmichael JC, Chiu H-
926 p, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I, Arinsburg S, Bandres JC, Siddiquey MN,
927 Schilke RM, Woolard MD, Zhang H, Duty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK,
928 Gamarnik AV, Hioe CE, Zolla-Pazner S, Ivanov SS, Kamil JP, Krammer F, Lee B. 2020.
929 Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus
930 neutralization assay allows for cross-cohort comparisons of COVID-19 sera. mBio 12.
931 87. Anonymous. Wu, Fan and Wang, Aojie and Liu, Mei and Wang, Qimin and Chen, Jun and Xia,
932 Shuai and Ling, Yun and Zhang, Yuling and Xun, Jingna and Lu, Lu and Jiang, Shibo and Lu,
933 Hongzhou and Wen, Yumei and Huang, Jinghe, Neutralizing Antibody Responses to SARS-
934 CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications (3/28/2020). Available
935 at SSRN: https://ssrn.com/abstract=3566211 or http://dx.doi.org/10.2139/ssrn.3566211.
936 88. Beltrán-Pavez C, Riquelme-Barrios S, Oyarzún-Arrau A, Gaete-Argel A, González-Stegmaier R,
937 Cereceda-Solis K, Aguirre A, Travisany D, Palma-Vejares R, Barriga GP, Gaggero A, Martínez-
938 Valdebenito C, Corre NL, Ferrés M, Balcells ME, Fernandez J, Ramírez E, Villarroel F, Valiente-
939 Echeverría F, Soto-Rifo R. 2021. Insights into neutralizing antibody responses in individuals
940 exposed to SARS-CoV-2 in Chile. 7:eabe6855.
941 89. Bennett-Guerrero E, Romeiser JL, Talbot LR, Ahmed T, Mamone LJ, Singh SM, Hearing JC,
942 Salman H, Holiprosad DD, Freedenberg AT, Carter JA, Browne NJ, Cosgrove ME, Shevik ME,
943 Generale LM, Andrew MA, Nachman S, Fries BC. 2021. Severe Acute Respiratory Syndrome
944 Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019

Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial. Crit Care Med doi:10.1097/ccm.0000000000005066.

90. Holm K, Lundgren M, Kjedlsen-Kragh J, Ljungquist O, Bottiger B, Wiken C, Oberg J, Fernstrom N, Rosendal E, Overby A, Bystrom J, Forsell M, Landin-Olsson M, Rasmussen M. 2021. Convalescent plasma treatment of COVID-19: Results from a prematurely terminated randomized controlled open-label study in Southern Sweden. BMC Research Note.

91. Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, Abdulamir AS. 2020. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med 28:357-366.

92. Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, Ferrés M, Chang M, Vizcaya C, Mondaca S, Huete Á, Castro R, Sarmiento M, Villarroel L, Pizarro A, Ross P, Santander J, Lara B, Ferrada M, Vargas-Salas S, Beltrán-Pavez C, Soto-Rifo R, Valiente-Echeverría F, Caglevic C, Mahave M, Selman C, Gazitúa R, Briones JL, Villarroel-Espindola F, Balmaceda C, Espinoza MA, Pereira J, Nervi B. 2020. Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial. PLoS Medicine doi:10.1371/journal.pmed.1003415.

93. AlQahtani M, Abdulrahman A, Almadani A, Alali SY, Al Zamrooni AM, Hejab AH, Conroy RM, Wasif P, Atkin SL, Otoom S, Abduljalil M. 2020. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci Rep 11:9927.

94. Bajpai M, Kumar S, Maheshwari A, Chhabra K, kale P, Gupta A, Narayanan A, Gupta E, Trehanpati N, Bihari C, Agarwal R, Gupta K, Gupta Uk, Bhardwaj A, Kumar G, Islam M, Singh R, Yadav P, Maiwall R, Sarin SK. 2020. Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial. medRxiv doi:10.1101/2020.10.25.20219337 %J medRxiv:2020.10.25.20219337.

95. Bégin P, Callum J, Heddle NM, Cook R, Zeller MP, Tinmouth A, Fergusson DA, Cushing MM, Glesby MJ, Chassé M, Devine DV, Robitalle N, Bazin R, Shehata N, Finzi A, McGeer A, Scales DC, Schwartz L, Turgeon AF, Zarychanski R, Daneman N, Carl R, Amorim L, Gabe C, Ellis M, Sachais BS, Loftsgard KC, Jamula E, Carruthers J, Duncan J, Lucier K, Li N, Liu Y, Armali C, Kron A, Modi D, Auclair MC, Cerro S, Avram M, Arnold DM. 2021. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials 22:323.

96. Bégin P, Callum J, Jamula EJ, Cook R, Heddle NM, Tinmouth A, Zeller MP, Beaudoin-Bussière G, Amorim L, Bazin R, Cadogan Lofstgard K, Carl R, Chassé M, Cushing M, Daneman N, Devine DV, Dumaresq J, Ferguson D, Gabe C, Glesby MJ, Li N, Liu Y, McGeer A, Robitaille N, Sachais BS, Scales DC, Schwartz L, Shehata N, Turgeon A, Wood H, Zarychanski R, Finzi A, Arnold DM. 2021. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. medrXiv [Preprint] doi:10.1101/2021.06.29.21259427 %J medRxiv:2021.06.29.21259427.

97. Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, Bhimani Z, Bonten M, Broglio K, Brunkhorst F, Cheng AC, Chiche JD, De Jong M, Detry M, Goossens H, Gordon A, Green C, Higgins AM, Hullegie SJ, Kruger P, Lamontagne F, Litton E, Marshall J, McGlothlin A, McGuinness S, Mouncey P, Murthy S, Nichol A, O'Neill GK, Parke R, Parker J, Rohde G, Rowan K, Turner A, Young P, Derde L, McArthur C, Webb SA. 2020. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc 17:879-891.

98. Estcourt LJ. 2021. Convalescent Plasma in Critically ill Patients with COVID-19. medrXiv [Preprint] doi:10.1101/2021.06.11.21258760 %J medRxiv:2021.06.11.21258760.

99. Anonymous. National COVID19 Convalescent Plasma Project. Commentary from the COVID-19 Convalescent Plasma Project (CCPP19) Leadership Group on "Early Convalescent Plasma

for High-Risk Outpatients with Covid-19". Accessed online at https://ccpp19.org/news/review%20of%20NEJM%20US%20outpatient%20CP%20trial%208-23.docx on August 25, 2021.

100. Anonymous. March 2, 2021. NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms. https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms. Accessed

101. Beltran Gonzalez JL, Gonzalez Gamez M, Mendoza Enciso EA, Esparza Maldonado RJ, Hernandez Palacios D, Duenas Campos S, Ovalle Robles I, Macias Guzman MJ, Garcia Diaz AL, Gutierrez Pena CM, Reza Escalera AL, Tiscareno Gutierrez MT, Galvan Guerra E, Dorantes Morales MdR, Martinez Medina L, Monroy Colin VA, Arreola Guerra JM. 2021. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. medrXiv [Preprint] doi:10.1101/2021.03.28.21254507 %J medRxiv:2021.03.28.21254507.

102. Sekine L, Arns B, Fabro BR, Cipolatt MM, Machado RRG, Durigon EL, Parolo E, Pellegrini JAS, Viana MV, Schwarz P, Lisboa TC, Dora JMS, Balsan AM, Schirmer FD, Franz JPM, da-Silveira LM, Breunig RC, Petersen V, Sosnoski M, Mesquita NF, Volpato FCZ, Sganzerla D, Falavigna M, Rosa RG, Zavascki AP. 2021. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J doi:10.1183/13993003.01471-2021.

103. Devos T, Van Thillo Q, Compernolle V, Najdovski T, Romano M, Dauby N, Jadot L, Leys M, Maillart E, Loof S, Seyler L, Moonen M, Moutschen M, Van Regenmortel N, Ariën KK, Barbezange C, Betrains A, Garigliany M, Engelen MM, Gyselinck I, Maes P, Schauwvlieghe A, Liesenborghs L, Belmans A, Verhamme P, Meyfroidt G. 2021. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J doi:10.1183/13993003.01724-2021.

104. Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. 2020. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 21:981.

105. Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, De Socio G, Luchi S, Blanc P, Puoti M, De Donno G, Toschi E, Massari M, Palmisano L, Marano G, Chiamenti M, Martinelli L, Franchi S, Pallotto C, Suardi L, Luciani Pasqua B, Merli M, Fabiani P, Bertolucci L, Borchi B, Modica S, Moneta S, Marchetti G, d'Arminio Monforte A, Stoppini L, Ferracchiato N, Piconi S, Fabbri C, Beccastrini E, Saccardi R, Giacometti A, Esperti S, Pierotti P, Bernini l, Bianco C, Benedetti S, Lanzi A, Bonfanti P, Massari M, Sani S, Saracino A, Castagna A, Trabace l, Lanza M, Focosi D, et al. 2021. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients with COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Network Open.

106. Jiang W, Li W, Xiong L, Wu Q, Wu J, He B, Shen J, Pang R, Luo T, Guo Y, Yang Y, Han Y, Dai W, Zhu P, Xia X. 2020. Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis. Clin Transl Med 10:e259.

107. Pappa V, Bouchla A, Terpos E, Thomopoulos TP, Rosati M, Stellas D, Antoniadou A, Mentis A, Papageorgiou SG, Politou M, Kotanidou A, Kalomenidis I, Poulakou G, Jahaj E, Korompoki E, Grigoropoulou S, Hu X, Bear J, Karaliota S, Burns R, Pagoni M, Trontzas I, Grouzi E, Labropoulou S, Stamoulis K, Bamias A, Tsiodras S, Felber BK, Pavlakis GN, Dimopoulos MA. 2021. A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. Microorganisms 9:806.

108. Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ, Chen J, Castillo B, Leveque C, Towers DM, Lavinder J, Gollihar JD, Cardona J, Ippolito GC, Nissly RH, Bird IM, Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary IB, Cattadori IM, Hudson PJ, Joselyn N, Prugar L, Huie K, Herbert A, Bernard DW, Dye J, Kapur V, Musser JM. 2020. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest 130:6728-6738.

109. Tworek A, Jaroń K, Uszyńska-Kałuża B, Rydzewski A, Gil R, Deptała A, Franek E, Wójtowicz R, Życińska K, Walecka I, Cicha M, Wierzba W, Zaczyński A, Król ZJ, Rydzewska G. 2021. Convalescent plasma treatment is associated with lower mortality and better outcomes in high risk COVID-19 patients - propensity score matched case-control study. Int J Infect Dis 105:209-215.

110. Chauhan L, Pattee J, Ford J, Thomas C, Lesteberg K, Richards E, Loi M, Dumont LJ, Annen K, Berg M, Zirbes M, Miller A, Jenkins TC, Bennett TD, Monkowski D, Boxer RS, Beckham JD. 2021. A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients. medrXiv [Preprint] doi:10.1101/2021.06.14.21258910 %J medRxiv:2021.06.14.21258910.